院股份有限公司

Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 2120

2024

INTERIM REPORT

Contents

C , A E I F A I 2

FI A CIA HIGH IGH 4

A AGE E DI C_ I A D A A I 5

C , A E G \5E A CE A D HE I F A I 31

C IDA ED BA A CE HEE 41

, A E C , A BA A CE HEE 45

C IDA ED I C E A E E 49

, A E C , A I C E A E E 52

C IDA ED CA H F A E E 54

, A E C , A CA H F A E E 57

C IDA ED A E E F CHA GE I HA EH DE ' E _ I 59

, A E C , A A E E F CHA GE I HA EH DE ' E _ I 61

E HE FI A CIA A E E 63

DEFI I I 151

Corporate Information

B D

Executive Directors

. G A (C)
. A G
. A G J

Non-executive Directors

. I H
. I C

Independent Non-executive Directors

. H G
. JI
. CHA H

A C

. H G (C)
. I C
. JI

C

. CHA H (C)
. G A
. JI

C

. JI (C)
. H G
. CHA H

C

. G A (C)
. H G
. I H

C

. - (C)
. -
. HA G
. IE
. IA C

J C

. A G J
. G C

A Z

. G A
. G C

A

BD C C A

A Z H

C C

H C

H D C

Corporate Information

B

H

40/F, D F C
248 E
H

H

C H
1712-1716, 17F
H C
183 E
H

C

2120

C

L Z

: (86) 577 8877 1689
F : (86) 577 8878 9117
E : @

Financial Highlights

F D

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	( )
Z	828,957	777,925
	61,513	60,207
	16,516	11,478
	44,996	48,729
C	50,724	43,750
	-5,727	4,979
Z	116,536	113,591

	As at	D	A
	June 30, 2024		31, 2023
	(RMB'000)		(B'000)
	(Unaudited)		(A)
	3,008,352		3,047,687
	1,581,890		1,639,481
	1,426,462		1,408,206
E C	1,290,906		1,265,065
	135,555		143,141

Management Discussion and Analysis

B_ I E E5IE A D _

L 2024, C F G .

L 2024, G B829.0 6.6% . A B765.6 5.1% . D G C B50.7 15.9% . A J 30, 2024, G 32 (D 31, 2023: 32), (H), 11,648 (D 31, 2023: 11,268).

Psychiatric Healthcare Business

G G G .

Management Discussion and Analysis



Elderly Healthcare Business



Management Discussion and Analysis

L 2024, G 2,730 Z B238.1 31.1% G Z . A G H C H H 2022, Z C C G H 2022, . H Z C H 2021, Z .

L J 2024, G C D H 2024 (《深化醫藥衛生體制改革2024年重點工作任務》), Z Z Z Z (固本革新,篤信行遠), H Z Z Z G Z G .

Management Discussion and Analysis

F

G B829.0 6.6%
2023. A
B765.6 5.1% 2023. D
G 27.5% (J 30,
2023: 24.9%). G B226.2 12.2%
2023. D
C B50.7 15.9%
2023. D G
B116.5 (J 30, 2023: B113.6), 2.6%
2023.

Revenue and Cost of Revenue

G : ( ) ; ( )
; ( ) :

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	( )
	765,636	728,692
	63,023	46,375
	298	2,858
Total revenue	828,957	777,925

Management Discussion and Analysis

(Billing Revenue)

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	(-)
B	784,892	744,197
	19,256	15,505
	765,636	728,692

5.5% 2023, B784.9

B19.3 B3.8 2023, B

2.5% (J 30, 2023: 2.1%).

Management Discussion and Analysis

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	( )
Billing Revenue from owned hospitals	784,892	744,197
C	555,218	547,492
G	229,674	196,705

B784.9

B40.7

2023,

2023. D

16.8%

2023,

Management Discussion and Analysis

	For the six months ended June 30,	
	2024	2023
	(Unaudited)	( )
Inpatients		
	11,648	10,578
E	2,119,936	1,914,618
(%)	87.4	84.0
	1,852,397	1,607,422
(B'000)	586,146	553,572
A	317	345
(B'000)	91,056	84,197
A *(B)*	49	52
Total inpatient revenue *(RMB'000)*	677,202	637,769
Total average inpatient spending per bed-day *(RMB)*	366	397
Outpatients		
	243,108	250,648
(B'000)	31,560	33,647
A *(B)*	130	134
(B'000)	76,130	72,781
A *(B)*	313	291
Total outpatient revenue *(RMB'000)*	107,690	106,428
Total average outpatient spending per visit *(RMB)*	443	425
Total treatment and general healthcare services revenue *(RMB'000)*	617,706	587,219
Total pharmaceutical sales revenue *(RMB'000)*	167,186	156,978

Management Discussion and Analysis

[illegible] B677.2 [illegible] 6.2% [illegible] 2023, [illegible] G [illegible] 15.2%, [illegible] G [illegible] H [illegible] H [illegible] C [illegible] H [illegible] H [illegible] G [illegible] H [illegible] H [illegible] D [illegible] H [illegible] C [illegible] H [illegible] 2023. [illegible] B [illegible] 86.3% ([illegible] J [illegible] 30, 2023: 85.7%).

[illegible] B107.7 [illegible] 1.2% [illegible] 2023, [illegible] 4.2% [illegible] 3.0%. [illegible] B [illegible] 13.7% ([illegible] J [illegible] 30, 2023: 14.3%).

[illegible] B [illegible] 5.2% [illegible] 2023, [illegible] 78.7% ([illegible] J [illegible] 30, 2023: 78.9%) B [illegible] ; B [illegible] 6.5% [illegible] 2023, [illegible] 21.3% ([illegible] J [illegible] 30, 2023: 21.1%) B [illegible] B [illegible] 13.4% ([illegible] J [illegible] 30, 2023: 13.2%), [illegible] B [illegible] 70.7% ([illegible] J [illegible] 30, 2023: 68.4%).

C [illegible] G [illegible] G [illegible] :

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	([illegible])
[illegible]	177,398	188,867
E [illegible]	228,188	208,780
D [illegible]	14,557	17,993
D [illegible]	52,308	49,033
C [illegible]	33,351	32,373
[illegible]	8,450	10,630
[illegible]	40,966	39,816
Cost of revenue of owned hospitals	555,218	547,492

Management Discussion and Analysis

D B555.2 1.4% 2023. I : ( ) 9.3% ; ( ) 6.1% ; ( ) 0.2% 2023.

F 32.0% (J 30, 2023: 34.5%). 41.1% (J 30, 2023: 38.1%). 12.0% (J 30, 2023: 12.2%).

G . D G B63.0 B41.7 (J 30, 2023: B29.1).

G . D B0.3 (J 30, 2023: B2.9), H

Management Discussion and Analysis

Gross Profit and Gross Profit Margin

D 12.2% G B226.2 2023. B210.4 16.1% 2023. :

	For the six months ended June 30,	
	2024	2023
	(Unaudited)	( )
	27.5%	24.9%
	24.9%	41.3%
Consolidated gross profit margin	27.3%	25.9%

D J 30, 2023: 25.9%), G 27.3% (2.6 2023.

Tax and Surcharge

D G B6.3 (J 30, 2023: B2.8).

Selling Expenses

D G B9.2 (J 30, 2023: B7.8). 1.2% G (J 30, 2023: 1.1%).

Management Discussion and Analysis

Administrative Expenses

D [illegible] G [illegible]

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	( )
E	64,383	55,922
D	13,955	13,474
C	4,042	14,377
	2,199	2,071
	21,692	16,080
Total administrative expenses	106,271	101,924

D [illegible] G [illegible] B106.3 [illegible] 4.3% [illegible] 2023, [illegible] 15.1% [illegible] 2023 [illegible] 71.9% [illegible] 2023. D [illegible] G [illegible] 13.9% ([illegible] J [illegible] 30, 2023: 14.0%).

Management Discussion and Analysis

Research and Development Expenses

D [illegible] E [illegible] G [illegible] :

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	( )
C	12,779	9,691
[illegible] D	4,035	3,259
C [illegible] H	748	1,982
	26	26
Total	17,588	14,958

D [illegible] G [illegible] B17.6 [illegible] J 30, 2023: B15.0), 17.6% 2023. G 2.3% (J 30, 2023: 2.1%).

Management Discussion and Analysis

Finance Expenses – Net

[illegible]

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	(– • •)
L –	-2,686	-2,705
F – /	99	-13
B –	18,078	14,124
L –	5,245	5,058
– • –	2,968	3,151
	761	545
Finance expenses – net	24,465	20,160

D – / – • , – – G – B24.5 – , – – – B4.3 – – – 2023, – – – – – B4.0 – – – 2023.

Management Discussion and Analysis

Investment Income/Loss

[illegible]

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	(-)
[illegible]	479	-158
G / [illegible]	1,201	-38
	1,680	-196

D B1.4 [illegible] B1.7 [illegible] H [illegible] H C .,

Credit Impairment Losses

D [illegible] B5.6 (J 30, 2023: B3.0).

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses

[illegible]

For the six months ended June 30,	
2024	2023
(RMB'000)	(B'000)
(Unaudited)	(- •)

Management Discussion and Analysis

F /

Inventory

A J 30, 2024, B51.9 (D 31, 2023: B60.6),

Accounts Receivables

A J 30, 2024, B448.1 (D 31, 2023: B420.4), 6.6% D 31, 2023, G 95 (J 30, 2023: 91).

D

Other Receivables and Prepayments

A J 30, 2024, B72.3 (D 31, 2023: B79.5).

Other Non-current Financial Assets

A J 30, 2024, B64.8 (D 31, 2023: B65.1).

Construction in progress

A J 30, 2024, B234.0 (D 31, 2023: B187.0). D H C H

Right-of-use Assets

A J 30, 2024, B170.5 (D 31, 2023: B189.1),

Accounts Payables

A J 30, 2024, B112.5 (D 31, 2023: B110.1).

Management Discussion and Analysis

Receipts in Advance and Contract Liabilities

A J 30, 2024, B26.3 (D 31, 2023: B26.6).

Other Payables

A J 30, 2024, B68.5 (D 31, 2023: B150.3),

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	(-)
	116,536	113,591
	-112,711	-119,122
	-41,660	9,790
	-37,934	4,273

Net Cash Generated from Operating Activities

D B45.0 B79.4 B42.4 B5.6 B116.5

Net Cash Used in Investing Activities

D B111.0 B112.7

Management Discussion and Analysis

Net Cash Generated from Financing Activities

D B41.7

Significant Investment, Acquisition and Disposal

J 30, 2024.

A B

Bank Borrowings

A J 30, 2024, B923.3 (D 31, 2023: B864.7), B304.8 B363.4

Contingent Liability

A J 30, 2024,

Asset Pledge

D H D . 826751, D . 826750, (2016) E . 0010144, (2016) E . 0010142, (2021) E . 0081628, G (2015) . 1-11836, G (2015) . 1-11833 C B (2017) C C E . 0018361 C ICBC B . A J 30, 2024, B267.3 H (2020) E . 0068897 C B C C C . A J 30, 2024, B95.0 . J H (2022) J E . 0002503 J . 331122202000043 J C B . A J 30, 2024, B25.0 . H (2022) E . 0045588 C CI IC B . A J 30, 2024, B58.3 .

Management Discussion and Analysis

Lease Liabilities

[illegible] B158.9 [illegible] B22.8 [illegible]

Financial Instruments

[illegible]

Exposure to Fluctuation in Exchange Rates

[illegible]

Gearing Ratio

[illegible] 52.6% ([illegible] 31, 2023: 53.8%).

Employees and Remuneration Policy

[illegible] 4,742 [illegible] 31, 2023: 4,765 [illegible]. [illegible] B313.8 [illegible] 30, 2023: B291.5 [illegible]. [illegible] B132.4 [illegible].

[illegible] 2023 [illegible]

Management Discussion and Analysis

E

C E 2018 H C ., . (《溫州康寧醫院股份有限公司2018年股權激勵計劃》, Equity Incentive Scheme), C 2017 J 13, 2018. C A J 24, 2021, E ( ) B , C E . , 29, 2018, 30, 2018, 14, 2021, J 18, 2021 J 25, 2021 C .

E 165 , 1,818,529 . / 23 , 180,516 . / ( ) 13 , 540,229 . A 8 / , 79,274 . A E 193 , 2,460,000 . 3.2976% C 48 B10.47/ .

A 2,460,000 E J 18, 2021, E E

Management Discussion and Analysis

(1)

(2)

( )

( )

Management Discussion and Analysis

(3) D E

( ) F E

C C

( ) E

D C

( ) A E

C

2,460,000 E

3.30% C

4.45% D

(4) E

( ) E

E 10

2017 (. . A 26, 2018),

. A

E

4

( ) E

48

( ) E

48 (J 28, 2022)

(J 29, 2018);

E

Management Discussion and Analysis

(5) G E

( )

( ) C D G D

( ) D C

(Z) C ( ) C C

(Z) C E

(6) G E :G B10.47 ;G B10.47 .

( ) B G E B , G B10.47 E (重點激勵、有效激勵) :

( ) B (. . 29, 2018), H $40.00 (B32.50);

( ) E

( ) G E G E 32.22% C H , B10.47 .

Management Discussion and Analysis

F [illegible] J 30, 2024, [illegible] E [illegible]:

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/ Share)	Balance of Incentive Shares Granted but not Vested as at January 1, 2024	Balance of Incentive Shares Granted and Vested as at January 1, 2024	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares Granted but not Vested as at June 30, 2024
D.										
. A G	J 18, 2021	J 28, 2022	10.47		248,328					
Z										
. IE	J 18, 2021	J 28, 2022	10.47		4,776					
(. A GH)	J 18, 2021	J 28, 2022	10.47		28,653					
. A GH	J 18, 2021	J 28, 2022	10.47		95,511					
(. A G)										
. A GB ( )	J 18, 2021	J 28, 2022	10.47		4,776					
(. A G										
. A GH)										
. ( )	J 18, 2021	J 28, 2022	10.47		4,776					
( )										
G. A										
(G. A 667 (J 18 ( )) 0 -1.556 7( )-722 (( )) J21.26 1.556 (J 18,) 0.722 0 -1.556 (2021) 0 6.299 1.556 (J 28, 9 -589 -										
( ) ( )2021)										

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/ Share)	Balance of Incentive Shares Granted but not Vested as at January 1, 2024	Balance of Incentive Shares Granted and Vested as at January 1, 2024	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares Granted but not Vested as at June 30, 2024
[illegible]	A 20, 2018	J 28, 2022	10.47	·	133,715	·	·	·	·	·
	A 16, 2021	J 28, 2022	10.47	·	47,755	·	·	·	·	·
C [illegible]	A 20, 2018	J 28, 2022	10.47	·	1,605,540	·	·	·	·	·
	A 26, 2019	J 28, 2022	10.47	·	180,516	·	·	·	·	·
	A 16, 2021	J 28, 2022	10.47	·	36,886	·	·	·	·	·
				·	2,460,000	·	·	·	·	·

A E D C

H A

A A C H A 2023 C 27, 2023. C 8, 2023 C 27, 2023, A 12, 2024, A 23, 2024 J 18, 2024.

Management Discussion and Analysis

H A C H A C H C C H 5% (3,730,015) C C B / D

H A 36 364,100 ( ) ( ) 36 616,000 52 335,000 . A 7 75,000 . A H A 101 1,240,100 1.66% C F C 8, 2023 C 27, 2023, A 12, 2024, A 23, 2024 J 18, 2024.

Corporate Governance and Other Information

C / A E G \5E A CE

D CG C .

C / IA CE I H HE DE C DE

C C . B D D J 1, 2024 J 30, 2024

Corporate Governance and Other Information

ADDITIONAL DISCLOSURE OF THE INTERIM REPORT

C A C 3.21 3.22 H CG C A C B . A J 30, 2024, A C D , . H G (A C) . JI D , . IC . A C J 30, 2024

INTERIM DIVIDEND

B DZ . B 2024 (C), B1.50 ( ) 10 . A INTERIM ACCOUNTS OF THE ENDED JUNE 30, 2024 C , C 74,600,300 . E 751,900 H B11,077,260 ( ), 21.81% DZ B. D B H H DZ H H B B C EG C). 2024 EG C .

DZ EG , DZ 18, 2024.

Corporate Governance and Other Information

E C (中華人民共和國企業所得稅法)
J 1, 2008, C
10%
H . A H
H CC
I H C
H
D .

I H H
10% C C
C 10%.
H 10%
C C
10%. H
10%
C
C H C
H
10% 20% C
C H
20%
C C,
20%.

CHA E, A E EDE I F I ED EC_ I IE

D C
C ( ).

A J 30, 2024, G

Corporate Governance and Other Information

CHA GE I DI EC , - / E \5I A D E I A AGE E

C

E5E AF E HE E / I G / E I D

G

CHA GE I DI EC ', - / E \5I ' A D CHIEF E EC \5E' BI G A HICA DE AI /

J 1, 2024 J 30, 2024 13.51B H :

Name	Members of the Group	Positions held at members of the Group	Term of office
A G	G F H C ., .	E D ,	F 2024
A GJ	G H C ., .	E D	F A 2024

C D ', 13.51B H

Corporate Governance and Other Information

DI C _ E FI E E

Directors', Supervisors' and Chief Executive's Interests in Securities

A J 30, 2024, D , Z Z
C C
(F) C H E
DZ 7 8 / 5 F (/ Z Z F), C 352 F , C H E
C :

Name of Directors	Class of Shares	Nature of Interest	Number of Shares	Total Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Shares[1]
. G A [2]	D	B	18,350,250( )	22,044,750( )	39.89%	29.55%
			3,694,500( )			
. A G [2]	D	B	3,694,500( )	22,044,750( )	39.89%	29.55%
			18,350,250( )			
	H	B	149,300( )	149,300( )	0.77%	0.20%
. A G J	D	B	100,000( )	100,000( )	0.18%	0.13%
	H	B	159,100( )	159,100( )	0.82%	0.21%
. [3]	D		4,540,000( )	4,540,000( )	8.22%	6.09%

:

( ):

(1) 55,260,000 D 19,340,300 H (74,600,300) C J 30, 2024.

(2) . G A . A G , . G A D . A G . A G D . G A Z / 5 F .

(3) 50% J E C ( ) (上海金浙企業管理中心(有限合夥)) J E C ( ) (上海金浙企業管理中心(有限合夥)) J E ( ). Z / 5 F , D Z C .

Corporate Governance and Other Information

[illegible]

Interests of Substantial Shareholders

[illegible]

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Shares Capital[1]
C E L F C ., . (中央企業鄉村產業投資基金股份有限公司)	D	B	7,466,666( )	13.51%	10.00%
J E C ( ) (上海金淅企業管理中心(有限合夥))[2]	D		4,540,000( )	8.22%	6.09%
FA [2]	D		4,540,000( )	8.22%	6.09%
J [2]	D		4,540,000( )	8.22%	6.09%

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Shares Capital[1]
(上海金浦健服股權投資管理有限公司)[2]	D		4,540,000( )	8.22%	6.09%
(溫州金寧股權投資合夥企業(有限合夥))	D	B	4,540,000( )	8.22%	6.09%
[6]	D		3,984,350( )	7.21%	5.34%
(上海檀英投資合夥企業(有限合夥))	D	B	4,519,003( )	8.18%	6.06%
(上海樂進投資合夥企業(有限合夥))[3]	D		4,519,003( )	8.18%	6.06%
	D		6,506,309( )	11.77%	8.72%
(上海正心谷投資管理有限公司)	D		6,506,309( )	11.77%	8.72%
(上海盛歌投資管理有限公司))[4]					
(萬得信息技術股份有限公司)	D		3,333,000( )	6.03%	4.47%
(上海荷花緣企業管理中心(有限合夥))	D		3,333,000( )	6.03%	4.47%

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Shares Capital[1]
(Wind Investment) (萬得影響力股權投資(嘉興)合夥企業(有限合夥))	D	B	3,333,000( )	6.03%	4.47%
CI IC (中信証券投資有限公司)	D	B	2,780,000( )	5.03%	3.73%
CI IC (中信証券股份有限公司)[5]	D		2,780,000( )	5.03%	3.73%
	H		1,454,000( )	7.52%	1.95%
	H		2,150,900( )	11.12%	2.88%
	H	B	1,279,900( )	6.62%	1.72%
	H	B	1,052,000( )	5.44%	1.41%
	H		1,029,400( )	5.32%	1.38%
(鄒海麗)	H	B	1,680,000( )	8.69%	2.25%
[6]	D H	B B	3,984,350( ) 309,000( )	7.21% 1.60%	5.34% 0.41%
	H		1,547,500( )	8.00%	2.07%
(H)	H		1,547,500( )	8.00%	2.07%

Corporate Governance and Other Information

:

( ):

(1) 55,260,000 D 19,340,300 H (74,600,300) C J 30, 2024.

(2) FA 50% C ( ) (上海金淅企業管理中心(有限合夥)) C ( ) (上海金淅企業管理中心(有限合夥)) E ( ) (溫州金寧股權投資合夥企業(有限合夥)). J 33.94% E ( ) (溫州金寧股權投資合夥企業(有限合夥)). J E C .. . (上海金浦健服股權投資管理有限公司) E ( ). F , FA J E C ( ) (上海金淅企業管理中心(有限合夥)), J J E C .. . (上海金浦健服股權投資管理有限公司) D E ( ) (溫州金寧股權投資合夥企業(有限合夥)) C .

(3) . (上海樂進投資合夥企業(有限合夥)) 99.99% . (上海樂進投資合夥企業(有限合夥)). F , . (上海樂進投資合夥企業(有限合夥)) D . (上海檀英投資合夥企業(有限合夥)) C .

(4) C .. (上海正心谷投資管理有限公司) (C .. . (上海盛歌投資管理有限公司)) (.) (上海乾剛投資管理合夥企業(有限合夥)) . (上海檀英投資合夥企業(有限合夥)). F , C .. D . (上海檀英投資合夥企業(有限合夥)) C . (.) (上海乾剛投資管理合夥企業(有限合夥)) (1,987,356 D C) . (上海檀英投資合夥企業(有限合夥)) C .

(5) CI IC (中信証券投資有限公司) CI IC C . F , CI IC C D CI IC (中信証券投資有限公司) C .

(6) . A G H . D . A G H F .

Corporate Governance and Other Information

[illegible] J 30, 2024, [illegible] D [illegible] ([illegible] D [illegible] C) [illegible] C [illegible] DZ 2 3 /5 F , [illegible] C 336 F .

B B
Wenzhou Kangning Hospital Co., Ltd.
C
GUAN Weili

[illegible] C
16, 2024

Consolidated Balance Sheets

J 30, 2024

(A B)

ASSETS		Balance as at the end of the period	B
Current assets:			
C	( )	373,302,433.47	418,861,721.39
F	( )	7,599,178.13	7,350,298.53
D	( )	763,849.74	
A	( )	448,102,421.02	420,441,069.56
A	( )	2,366,951.74	9,830,552.98
	( )	69,943,027.66	69,705,728.98
F	( )	51,889,640.76	60,600,180.25
: D C A	( )	3,053,787.78	858,020.39
Total current assets		957,021,290.30	987,647,572.08

Consolidated Balance Sheets

J 30, 2024

(A B)

ASSETS		Balance as at the end of the period	B
Non-current assets:			
G			
D			
	( )	14,000,000.00	14,000,000.00
	( )	141,550,815.01	139,071,987.05
	( )	64,751,652.55	65,099,055.34
F	( )	782,127,103.00	794,856,342.94
C	( )	234,034,296.61	186,980,240.67
	( )	170,465,125.54	189,054,506.68
	( )	307,875,476.38	320,321,705.16
: D			
D			
: D			
G	( )	119,909,089.24	119,909,089.24
	( )	156,750,581.45	175,910,626.14
D	( )	44,940,518.91	45,146,270.60
	( )	14,925,823.45	9,689,210.94
Total non-current assets		2,051,330,482.14	2,060,039,034.76
Total assets		3,008,351,772.44	3,047,686,606.84

GUAN Weili JIN Hui H WANG Minhui

Consolidated Balance Sheets

J 30, 2024

(A B)

LIABILITIES AND SHAREHOLDERS' EQUITY		Balance as at the end of the period	B
Current liabilities:			
	( )	111,000,000.00	127,001,700.00
B			
F	( )	12,400,000.00	12,400,000.00
D			1,545,021.09
A	( )	112,544,938.03	110,060,007.67
	( )	26,157,511.69	26,563,603.06
C	( )	92,924.53	
F			
F			
F			
E	( )	67,014,464.52	84,324,006.40
	( )	30,855,445.81	38,553,746.47
	( )	68,487,137.05	150,270,575.15
F			
	( )	108,286,381.25	250,411,756.99
	( )	569,425.21	
Total current liabilities		537,408,228.09	801,130,416.83
Non-current liabilities:			
	( )	768,224,669.65	557,719,214.69
B			
	( )	158,912,952.10	163,239,532.76
	( )	64,227,913.88	61,351,340.53
D	( )	8,582,203.00	8,734,099.00
D	( )	44,533,949.56	47,306,056.21
Total non-current liabilities		1,044,481,688.19	838,350,243.19

Consolidated Balance Sheets

J 30, 2024

(A B)

LIABILITIES AND SHAREHOLDERS' EQUITY		Balance as at the end of the period	B
Total liabilities		1,581,889,916.28	1,639,480,660.02
Shareholders' equity:			
	( )	74,600,300.00	74,600,300.00
C	( )	840,753,480.74	852,695,601.69
	( )	3,146,832.71	12,587,011.74
	( )	38,399,577.13	38,399,577.13
	( )	340,299,883.36	311,956,229.16
Total equity attributable to shareholders of the parent company		1,290,906,408.52	1,265,064,696.24
Non-controlling interests		135,555,447.64	143,141,250.58
Total shareholders' equity		1,426,461,856.16	1,408,205,946.82
Total liabilities and shareholders' equity		3,008,351,772.44	3,047,686,606.84

GUAN Weili JIN Hui H WANG Minhui

Parent Company Balance Sheets

J 30, 2024

(A B)

ASSETS		Balance as at the end of the period	B
Current assets:			
C		167,239,404.12	186,837,559.21
F			
D			
A	( )	55,989,746.68	48,066,557.69
A		6,900.00	228,131.12
	( )	622,922,583.60	600,448,325.58
		9,687,901.11	11,181,002.59
: D			
C			
A			
		355,000.00	330,000.00
Total current assets		856,201,535.51	847,091,576.19

Parent Company Balance Sheets

J 30, 2024

(A B)

ASSETS		Balance as at the end of the period	B
Non-current assets:			
D	( )	793,380,629.16	785,983,439.17
		64,751,652.55	65,099,055.34
F		283,949,624.57	288,701,322.35
C		394,874.50	113,600.00
		23,105,075.42	23,680,002.23
G		16,120,799.75	18,459,271.72
D		16,099,597.14	14,608,690.36
		14,472,217.77	6,320,388.26
Total non-current assets		1,212,274,470.86	1,202,965,769.43
Total assets		2,068,476,006.37	2,050,057,345.62

GUAN Weili JIN Hui WANG Minhui

Parent Company Balance Sheets

J 30, 2024

(A B)

LIABILITIES AND SHAREHOLDERS' EQUITY		Balance as at the end of the period	B
Current liabilities:			
F D		111,000,000.00	125,000,000.00
A		37,382,041.07	33,774,329.53
		3,483,707.09	4,172,410.35
C			
E		16,652,661.89	20,572,854.31
		2,812,623.38	1,603,746.33
		42,052,422.61	38,919,608.73
		59,854,608.34	173,615,500.00
Total current liabilities		273,238,064.38	397,658,449.25
Non-current liabilities:			
B		506,300,000.00	362,042,127.25
		16,710,574.36	25,855,234.63
D		8,582,203.00	8,734,099.00
D			
Total non-current liabilities		531,592,777.36	396,631,460.88
Total liabilities		804,830,841.74	794,289,910.13

Parent Company Balance Sheets

J 30, 2024

(A B)

LIABILITIES AND SHAREHOLDERS' EQUITY		Balance as at the end of the period	B
Shareholders' equity:			
		74,600,300.00	74,600,300.00
C		862,663,919.13	871,230,628.64
		3,146,832.71	12,587,011.74
		38,399,577.13	38,399,577.13
		291,128,201.08	284,123,941.46
Total shareholders' equity		1,263,645,164.63	1,255,767,435.49
Total liabilities and shareholders' equity		2,068,476,006.37	2,050,057,345.62

GUAN Weili JIN Hui H WANG Minhui

Consolidated Income Statement

F J 30, 2024

(A B)

Item		Amount for the current period	A
I. Total revenue	( )	828,957,553.71	777,925,163.84
:	( )	828,957,553.71	777,925,163.84
F			
II. Total cost of sales		766,642,937.50	724,044,723.76
: C	( )	602,800,461.11	576,390,595.76
F			
	( )	6,268,298.95	2,783,861.65
	( )	9,249,266.44	7,828,610.00
G	( )	106,271,383.70	101,924,026.76
	( )	17,588,076.15	14,957,995.63
F	( )	24,465,451.15	20,159,633.96
:		23,323,466.98	19,182,137.46
		2,686,209.46	2,704,831.09
A :	( )	5,588,263.28	5,822,495.15
(-)	( )	1,680,199.57	-195,725.93
:		478,827.96	-157,522.45
D			
F (-)			
G (-)			
G (-)	( )	-98,523.19	
C (-)	( )	-5,584,264.01	-3,009,926.77
A (-)			
G (-)	( )	-74,985.41	

Consolidated Income Statement

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

Item	[illegible]	Amount for the current period	A [illegible]
III. Operating profit (losses represented with "-" sign)		63,825,306.45	56,497,282.53
A [illegible] : [illegible]	( )	503,489.95	5,924,960.98
: [illegible]	( )	2,816,219.76	2,215,131.37
IV. Total profit (total losses represented with "-" signs)		61,512,576.64	60,207,112.14
: [illegible]	( )	16,516,143.35	11,477,880.07
V. Net profit (net losses represented with "-" signs)		44,996,433.29	48,729,232.07
( ) C [illegible]			
1. [illegible] - [illegible])		44,996,433.29	48,729,232.07
2. [illegible] - [illegible])			
( ) C [illegible]			
1. [illegible] - [illegible])		50,723,744.20	43,750,057.46
2. [illegible] - [illegible])		-5,727,310.91	4,979,174.61
VI. Other comprehensive income, net of tax			

[illegible]

( ) [illegible]

1. C[illegible]

2. [illegible]

3. C[illegible]

4. C[illegible]

Consolidated Income Statement

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

Item	[illegible]	Amount for the current period	A [illegible]
( ) [illegible]			
1. [illegible]			
2. C [illegible]			
3. A [illegible]			
4. C [illegible]			
5. [illegible]			
6. E [illegible]			
7. [illegible]			
VII. Total comprehensive income		44,996,433.29	48,729,232.07
A [illegible]		50,723,744.20	43,750,057.46
A [illegible]		-5,727,310.91	4,979,174.61
VIII. Earnings per share:			
( ) B (B [illegible])	( )	0.68	0.59
( ) D (B [illegible])	( )	0.68	0.59

[illegible]

[illegible] :

GUAN Weili

[illegible] :

JIN Hui

H [illegible] :

WANG Minhui

Parent Company Income Statement

F [illegible] J 30, 2024

(A [illegible] B [illegible])

Item	[illegible]	Amount for the current period	A [illegible]
I. Revenue	(Z)	193,286,941.03	176,204,799.00
: C	(Z)	130,785,130.41	130,786,397.79
		3,245,018.31	140,434.74
		421,415.53	613,098.03
G		33,439,820.06	42,010,452.24
		12,778,787.81	9,690,626.11
F		7,528,437.05	8,063,326.82
:		13,692,407.18	11,787,407.21
		8,491,601.94	6,124,076.98
A :		2,425,821.83	1,314,851.41
( )	(Z)	14,189,338.60	-775,547.72
:		128,019.62	816,165.55
D			
G ( )			
G ( )		-347,402.79	
C ( )		6,859,241.73	114,004.00
A ( )			
G ( )			
II. Operating profit (losses represented with “-” signs)		28,215,331.23	-14,446,229.04
A :			5,600,210.07
:		321,888.39	1,517,392.82
III. Total profit (total losses represented with “-” signs)		27,893,442.84	-10,363,411.79
:		-1,490,906.78	-1,686,567.50
IV. Net profit (net losses represented with “-” signs)		29,384,349.62	-8,676,844.29
( )		29,384,349.62	-8,676,844.29
( )			

Parent Company Income Statement

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

Item	[illegible]	Amount for the current period	A [illegible]
V. Other comprehensive income, net of tax			
( ) [illegible]			
1. C[illegible]			
2. [illegible]			
3. C[illegible]			
4. C[illegible]			
( ) [illegible]			
1. [illegible]			
2. C[illegible]			
3. A [illegible]			
4. C[illegible]			
5. [illegible]			
6. E [illegible]			
7. [illegible]			
VI. Total comprehensive income		29,384,349.62	-8,676,844.29
VII. Earnings per share:			
( ) B (B [illegible])			
( ) D (B [illegible])			

[illegible]

[illegible] :

GUAN Weili

[illegible] :

JIN Hui

H [illegible] :

WANG Minhui

Consolidated Cash Flow Statement

F J 30, 2024

(A B)

Item	Amount for the current period	A
I. Cash flows from operating activities		
C	774,736,897.94	780,086,767.35
C		
C		
C	40,064,567.80	169,903,996.27
Sub-total of cash inflows of operating activities	814,801,465.74	949,990,763.62
C	264,247,149.21	279,096,560.43
C		
C		
C		
C	329,971,885.59	300,131,941.56
/	40,687,505.65	37,824,192.11
C	63,358,941.68	219,346,730.82
Sub-total of cash outflows of operating activities	698,265,482.13	836,399,424.92
Net cash flows from operating activities	116,535,983.61	113,591,338.70

Consolidated Cash Flow Statement

F [illegible] J 30, 2024

(A [illegible] B [illegible])

Item	Amount for the current period	A [illegible]
II. Cash flows from investing activities		
C [illegible]		8,249,457.77
C [illegible]		
[illegible]	644,865.42	26,383.01
[illegible]	432,733.42	
C [illegible]	1,077,598.84	8,275,840.78
C [illegible]	111,001,022.93	107,843,620.41
C [illegible]	2,000,000.00	3,866,900.00
[illegible]		15,187,013.06
C [illegible]	787,500.00	500,059.94
[illegible]	113,788,522.93	127,397,593.41

Consolidated Cash Flow Statement

F [illegible] J 30, 2024

(A [illegible] B [illegible])

Item	Amount for the current period	A [illegible]
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-99,244.67	13,070.04
V. Net increase in cash and cash equivalents	-37,934,050.43	4,272,913.65
A [illegible] : C [illegible]	404,723,339.37	258,595,990.97
VI. Cash and cash equivalents at the end of the period	366,789,288.94	262,868,904.62

[illegible]

[illegible] :

GUAN Weili

[illegible]

JIN Hui

[illegible] :

H [illegible]

WANG Minhui

Parent Company Cash Flow Statement

F J 30, 2024

(A B)

Item	Amount for the current period	A
I. Cash flows from operating activities:		
C	178,625,474.28	186,510,657.37
C	334,259,258.00	491,763,058.70
Sub-total of cash inflows of operating activities	512,884,732.28	678,273,716.07
C	66,197,024.94	80,195,550.90
C	84,545,764.25	80,891,274.33
/	2,949,959.92	438,877.67
C	338,808,072.60	463,041,604.81
Sub-total of cash outflows of operating activities	492,500,821.71	624,567,307.71
Net cash flows from operating activities	20,383,910.57	53,706,408.36
II. Cash flows from investing activities:		
C		16,657,744.50
C	13,273,818.98	
	10,427.00	
C		
Sub-total of cash inflows of investing activities	13,284,245.98	16,657,744.50
C	1,277,334.63	1,691,749.51
C	7,200,000.00	29,166,900.00
C		
Sub-total of cash outflows of investing activities	8,477,334.63	30,858,649.51
Net cash flows from investing activities	4,806,911.35	-14,200,905.01

Parent Company Cash Flow Statement

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

Item	Amount for the current period	A [illegible]
III. Cash flows from financing activities:		
C [illegible]		
C [illegible]	293,000,000.00	199,050,000.00
C [illegible]		
Sub-total of cash inflows of financing activities	293,000,000.00	199,050,000.00
C [illegible]	276,792,127.25	101,150,000.00
C [illegible]	35,406,263.84	12,364,450.26
C [illegible]	25,472,250.00	79,243,750.00
Sub-total of cash outflows of financing activities	337,670,641.09	192,758,200.26
Net cash flows from financing activities	-44,670,641.09	6,291,799.74
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-119,720.72	13,070.04
V. Net increase in cash and cash equivalents	-19,599,539.89	45,810,373.13
A [illegible] : C [illegible]	185,475,808.48	90,387,144.89
VI. Cash and cash equivalents at the end of the period	165,876,268.59	136,197,518.02

[illegible]

[illegible] :

GUAN Weili

[illegible]

JIN Hui

H [illegible]

WANG Minhui

Consolidated Statement of Changes in Shareholders' Equity

F [redacted] J [redacted] 30, 2024

(A [redacted] B [redacted])

Amount for the current period

Items	Equity attributable to owners of the parent company												Minority interests	Total owners' equity
	Other equity instruments			Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserves	Surplus reserves	Provision for general risk	Retained earnings	Subtotal			
	Share capital	Preferential shares	Perpetual bonds	Others										
I. Balance as at the end of the previous year	74,600,300.00				852,695,601.69	12,987,011.74			38,399,577.13		311,958,229.16	1,265,066,696.24	143,141,250.58	1,408,206,946.82
[redacted]														
[redacted]														
[redacted]														
II. Balance as at the beginning of the current year	74,600,300.00				852,695,601.69	12,987,011.74			38,399,577.13		311,958,229.16	1,265,066,696.24	143,141,250.58	1,408,206,946.82
III. Increases/decreases in the current period ("-" for decreases)					-11,942,120.95	-9,440,179.03					28,949,654.20	25,941,712.28	-7,585,802.94	18,255,909.34
[redacted]											50,722,744.20	50,722,744.20	-5,727,310.91	44,995,433.29
[redacted]					-8,566,709.51	-9,440,179.03						873,469.52	1,033,024.97	1,906,494.49
1. [redacted]					-9,334,383.19	-9,440,179.03						105,795.84	1,033,024.97	1,138,820.81
2. [redacted]														
3. [redacted]														
4. [redacted]					767,673.68							767,673.68		767,673.68
[redacted]											-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00
[redacted]														
1. [redacted]														
2. [redacted]											-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00
3. [redacted]														
4. [redacted]														
[redacted]														
1. [redacted]														
2. [redacted]														
[redacted]														
IV. Balance as at the end of the period	74,600,300.00				-3,375,411.44 840,753,480.74	3,146,832.71			38,399,577.13		340,289,883.36	-3,375,411.44 1,290,906,408.52	135,555,447.64	-3,375,411.44 1,426,461,856.16

[redacted]

GUAN Weiii [redacted] JIN Hui [redacted]

H [redacted] WANG Minhui [redacted]

Consolidated Statement of Changes in Shareholders' Equity

F J 30, 2024

(A B)

I. Balance as at the end of the previous year	74,600,000.00			865,078,533.30			38,999,577.13	239,506,534.49	1,201,584,944.86	124,317,673.97	1,325,902,618.83
II. Balances as at the beginning of the current year	74,600,000.00			865,078,533.30			38,999,577.13	239,506,534.49	1,201,584,944.86	124,317,673.97	1,325,902,618.83
III. Increases/decreases in the current period (" " for decreases)				-2,382,931.61	12,587,011.74			76,449,894.73	63,479,751.38	18,823,576.61	82,303,327.99	
( )								85,947,806.64	85,947,806.64	963,801.18	86,911,607.82	
( )					12,587,011.74				-12,587,011.74	20,730,686.31	8,143,674.57	
1. C					12,587,011.74				-12,587,011.74	20,730,686.31	8,143,674.57	
2. C												
3. A												
4.												
( ) D									-7,498,111.91	-7,498,111.91	-2,890,920.88	-10,389,032.79
1.												
2.									-7,498,111.91	-7,498,111.91	-2,890,920.88	-10,389,032.79
3.												
4.												
(Z)												
1.												
2.												
3.												
4.												
5.												
6.												
(Z)										-2,382,931.61	-2,382,931.61	
1.												
2.												
(Z)												
IV. Balance as at the end of the period	74,600,000.00			-2,382,931.61	12,587,011.74			852,695,801.69	311,956,229.16	-2,382,931.61	1,143,141,250.58	1,498,205,946.82

H WANG Minhui

GUAN Weili JIN Hui

Parent Company Statement of Changes in Shareholders' Equity

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

Items	Amount for the current period										
	Other equity instruments										
	Share capital	Preferential shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserves	Surplus reserves	Retained earnings	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				871,230,828.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49
[illegible]											
II. Balance as at the beginning of the current year	74,600,300.00				871,230,828.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49
III. Increases/decreases in the current period ("-" for decreases)					-8,566,709.51	-9,440,179.03				7,004,259.62	7,877,729.14
[illegible]										29,384,349.62	29,384,349.62
[illegible]					-8,566,709.51	-9,440,179.03					873,469.52
1. [illegible]					-9,334,383.19	-9,440,179.03					105,795.84
2. [illegible]											
3. [illegible]											
4. [illegible]					767,673.68						767,673.68
[illegible]										-22,380,090.00	-22,380,090.00
1. [illegible]											
2. [illegible]										-22,380,090.00	-22,380,090.00
3. [illegible]											
[illegible]											
1. [illegible]											
2. [illegible]											
3. [illegible]											
4. [illegible]											
5. [illegible]											
6. [illegible]											
[illegible]											
1. [illegible]											
2. [illegible]											
[illegible]											
IV. Balance as at the end of the period	74,600,300.00				862,663,919.13	3,146,832.71			38,399,577.13	291,128,201.08	1,263,645,164.63

[illegible]

GUAN Weili [illegible] JIN Hui [illegible]

H [illegible] WANG Minhui [illegible]

Parent Company Statement of Changes in Shareholders' Equity

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

I.	Balance as at the end of the previous year	74,600,300.00				871,230,628.64				38,399,577.13	241,903,691.18	1,226,134,196.95
II.	Balance as at the beginning of the current year	74,600,300.00				871,230,628.64				38,399,577.13	241,903,691.18	1,226,134,196.95
III.	Increases/decreases in the current period ("-" for decreases)						12,587,011.74				42,220,250.28	29,633,238.54
	( )										49,718,362.19	49,718,362.19
	( )						12,587,011.74					-12,587,011.74
	1.						12,587,011.74					-12,587,011.74
	2.											
	3.											
	4.											
	( )										-7,498,111.91	-7,498,111.91
	1.											
	2.										-7,498,111.91	-7,498,111.91
	3.											
	(Z)											
	1.											
	2.											
	3.											
	4.											
	5.											
	6.											
	(Z)											
	1.											
	2.											
	(Z)											
IV.	Balance as at the end of the period	74,600,300.00				871,230,628.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49

GUAN Weili JIN Hui WANG Minhui

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

I. G [illegible]

[illegible] H C ., [illegible]. ([illegible] C [illegible]) [illegible] [illegible] C [illegible] H [illegible] (溫州市康寧精神康復醫院) F [illegible] 1996. [illegible] C [illegible], H [illegible] D [illegible] C.

[illegible] 15, 2014, [illegible] C [illegible] H C ., [illegible]. (溫州康寧醫院股份有限公司).

[illegible] C [illegible] E [illegible] H [illegible] 20, 2015. [illegible] C [illegible]

Notes to the Financial Statements

F J 30, 2024
(A B)

II. B

(I) Basis of preparation

A B
E B Z
A B E A B
E Z F (Z
A B E), Z
C Z D C . 15
G Z F C C
G Z E H
H C

A Z Z
A B E . 32 F
F

G

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

II. B [illegible] (C [illegible])

(II) Going concern

[illegible]

(III) Statement of compliance with the Accounting Standards for Business Enterprises

[illegible] A [illegible] B [illegible] E [illegible]
F [illegible] C [illegible] J [illegible] 30, 2024 [illegible]
J [illegible] J [illegible] 2024.

III. [illegible]

(I) Major tax categories and tax rates

Tax categories	Tax basis	Tax rate
[illegible] (5A)	[illegible] 5A [illegible] ([illegible]) [illegible]	3%, 6%, 13%
[illegible]	B [illegible] 5A [illegible]	7%
F [illegible]	B [illegible] 5A [illegible]	5%
E [illegible]	B [illegible]	15%, 20%, 25%
C [illegible]		

Taxpayer	Income tax rate
[illegible] H [illegible] C ., .	15%
[illegible] J [illegible] H [illegible] C ., .	15%
[illegible] H [illegible] C ., .	20%

Notes to the Financial Statements

F J 30, 2024
(A B)

III.

(II) Preferential tax treatment

1. (C 72016 . 36) (醫療機構執業許可證).

2. 3%.

3. B (C 72016 . 36) 6% 3%.

4. A J 30, 2024, 2024. 15%

5. 8, 2023, (. G 202333001809) 28 15% J 1, 2023 31, 2026.

Notes to the Financial Statements

F J 30, 2024
(A B)

15.

: B D 31, 2023 ( ), J 30, 2024 ( ), J 30, 2024 ( ), J 30, 2023 ( ).

(I) Cash at bank and on hand

Items	Balance as at the end of the period	B
C	315,188.51	371,623.69
C	367,196,561.26	416,980,298.98
	5,790,683.70	1,509,798.72
	373,302,433.47	418,861,721.39

(II) Financial assets held for trading

Items	Balance as at the end of the period	B
F	7,599,178.13	7,350,298.53
:	7,599,178.13	7,350,298.53
	7,599,178.13	7,350,298.53

(III) Notes receivable

Items	Balance as at the end of the period	B
B	763,849.74	
	763,849.74	

Notes to the Financial Statements

F J 30, 2024
(A B)

5. (C)

(IV) Accounts receivable

1. A

Aging	Balance as at the end of the period	B
1	443,637,522.96	425,833,221.01
1 2	42,631,127.19	6,696,709.84
2 3	4,507,504.01	4,480,032.80
3	10,140,966.30	7,780,009.57
	500,917,120.46	444,789,973.22
	52,814,699.44	24,348,903.66
	448,102,421.02	420,441,069.56

2. A

Category	Balance as at the end of the period					B				
	Book balance		Provision for bad debts			B				
	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	(%)	A	(%)	B
	28,701,127.14	5.73	24,270,288.56	84.56	4,430,838.58	19,507,030.88	4.39	12,854,582.28	65.90	6,652,448.60
	28,701,127.14	5.73	24,270,288.56	84.56	4,430,838.58	19,507,030.88	4.39	12,854,582.28	65.90	6,652,448.60
	472,215,993.32	94.27	28,544,410.88	6.04	443,671,582.44	425,282,942.34	95.61	11,494,321.38	2.70	413,788,620.96
	472,215,993.32	94.27	28,544,410.88	6.04	443,671,582.44	425,282,942.34	95.61	11,494,321.38	2.70	413,788,620.96
	500,917,120.46	100.00	52,814,699.44		448,102,421.02	444,789,973.22	100.00	24,348,903.66		420,441,069.56

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(IV) Accounts receivable *(Continued)*

2. A [illegible]

[illegible]:

Item	Balance as at the end of the period				B [illegible]	
	Book balance	Provision for bad debts	Proportion of provision (%)	Reason for the provision	B [illegible]	
[illegible]	28,701,127.14	24,270,288.56	84.56	[illegible] EC	19,507,030.88	12,854,582.28
[illegible]	28,701,127.14	24,270,288.56			19,507,030.88	12,854,582.28

[illegible]:

I [illegible]:

Item	Balance as at the end of the period		
	Accounts receivable	Provision for bad debts	Proportion of provision (%)
[illegible]	472,215,993.32	28,544,410.88	6.04
[illegible]	472,215,993.32	28,544,410.88	

Notes to the Financial Statements

F [illegible] J[illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C[illegible])

(IV) Accounts receivable *(Continued)*

3. [illegible]

Category	B [illegible]	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
[illegible]	12,854,582.28		-11,415,706.28			24,270,288.56
[illegible]	11,494,321.38	17,050,089.50				28,544,410.88
	24,348,903.66	17,050,089.50	-11,415,706.28			52,814,699.44

(V) Advances to suppliers

[illegible] :

Aging	Balance as at the end of the period		B [illegible]	
	Amount	Proportion (%)	A [illegible]	[illegible] (%)
[illegible] 1 [illegible]	2,326,232.07	98.28	9,048,941.18	92.05
1 2 [illegible]			742,811.80	7.56
2 3 [illegible]	7,919.67	0.33	6,000.00	0.06
[illegible] 3 [illegible]	32,800.00	1.39	32,800.00	0.33
	2,366,951.74	100.00	9,830,552.98	100.00

Notes to the Financial Statements

F [illegible] J[illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C[illegible])

(VI) Other receivables

Items	Balance as at the end of the period	B[illegible]
[illegible]	787,500.00	
[illegible]	69,155,527.66	69,705,728.98
[illegible]	69,943,027.66	69,705,728.98

1. [illegible]

[illegible]

Items	Balance as at the end of the period	B[illegible]
[illegible]	787,500.00	
[illegible]	787,500.00	

2. [illegible]

(1) D[illegible]

Aging	Balance as at the end of the period	B[illegible]
[illegible] 1 [illegible]	50,656,821.58	53,412,990.26
1 - 2 [illegible]	15,533,337.46	29,894,811.69
2 - 3 [illegible]	33,706,673.72	8,912,677.15
3 - 4 [illegible]	1,438,191.47	5,404,423.07
4 - 5 [illegible]	1,977,221.69	742,744.83
[illegible] 5 [illegible]	4,436,981.60	3,885,239.68
[illegible]	107,749,227.52	102,252,886.68
[illegible]	38,593,699.86	32,547,157.70
[illegible]	69,155,527.66	69,705,728.98

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(VI) Other receivables *(Continued)*

2. [illegible] (C [illegible])

(2) D [illegible]

	Balance as at the end of the period					B [illegible]				
	Book balance		Provision for bad debts			B [illegible]				
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A [illegible]	(%)	A [illegible]	(%)	B [illegible]
[illegible]	36,761,735.90	34.12	36,761,735.90	100.00		37,404,736.41	36.58	30,697,494.28	82.07	6,707,242.13
[illegible]	23,066,977.13	21.41	23,066,977.13	100.00		23,709,977.64	23.19	17,002,735.51	71.71	6,707,242.13
[illegible]	10,204,311.69	9.47	10,204,311.69	100.00		10,204,311.69	9.98	10,204,311.69	100.00	
[illegible] (汪長勝)	3,490,447.08	3.24	3,490,447.08	100.00		3,490,447.08	3.41	3,490,447.08	100.00	
[illegible]	70,987,491.62	65.88	1,831,963.96	2.58	69,155,527.66	64,848,150.27	63.42	1,849,663.42	2.85	62,998,486.85
[illegible]	70,987,491.62	65.88	1,831,963.96	2.58	69,155,527.66	64,848,150.27	63.42	1,849,663.42	2.85	62,998,486.85
	107,749,227.52	100.00	38,593,699.86		69,155,527.66	102,252,886.68	100.00	32,547,157.70		69,705,728.98

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(VI) Other receivables *(Continued)*

2. [illegible] (C [illegible])

(2) [illegible] (C [illegible])

Name	Balance as at the end of the period			B [illegible]	B [illegible]
	Book balance	Provision for bad debts	Proportion of provision (%)		
H [illegible] H C., [illegible] H [illegible]	23,066,977.13	23,066,977.13	100.00	E [illegible]	23,709,977.64	17,002,735.51
[illegible] C., [illegible]	10,204,311.69	10,204,311.69	100.00	E [illegible]	10,204,311.69	10,204,311.69
C [illegible] (汪長勝)	3,490,447.08	3,490,447.08	100.00	E [illegible]	3,490,447.08	3,490,447.08
	36,761,735.90	36,761,735.90			37,404,736.41	30,697,494.28

[illegible]:

I [illegible]:

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
[illegible]	70,987,491.62	1,831,963.96	2.58
	70,987,491.62	1,831,963.96	

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(VI) Other receivables *(Continued)*

2. [illegible] (C [illegible])

(3) D [illegible]

Provision for bad debts	Stage I 12-month ECL	Stage II Lifetime ECL (not credit impaired)	Stage III Lifetime ECL (credit impaired)	Total
B [illegible]	1,849,663.42		30,697,494.28	32,547,157.70
B [illegible] / II III II I			6,064,241.62	6,064,241.62
	17,428.98			17,428.98
	270.48			270.48
B [illegible]	1,831,963.96		36,761,735.90	38,593,699.86

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(VI) Other receivables *(Continued)*

2. [illegible] (C [illegible])

(3) D [illegible] (C [illegible])

C [illegible] :

Book balance	Stage I 12-month ECL	Stage II Lifetime ECL (not credit impaired)	Stage III Lifetime ECL (credit impaired)	Total
B [illegible]	64,848,150.27		37,404,736.41	102,252,886.68
B [illegible] / [illegible] II [illegible] III [illegible] II [illegible] I				
A [illegible]	6,139,341.35			6,139,341.35
D [illegible]			643,000.51	643,000.51
B [illegible]	70,987,491.62		36,761,735.90	107,749,227.52

Notes to the Financial Statements

F J 30, 2024

(A B)

5. (C)

(VI) Other receivables *(Continued)*

2. (C)

(4)

Category	B	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
	30,697,494.28	6,064,241.62				36,761,735.90
	1,849,663.42		17,428.98	270.48		1,831,963.96
	32,547,157.70	6,046,241.62	17,428.98	270.48		38,593,699.86

(5)

	Book balance as at the end of the period	B
D	22,840,821.05	22,266,761.49
E	25,289,000.00	19,150,000.00
	1,583,692.95	4,818,862.51
A	23,134.70	51,045.33
A	51,845,560.25	52,887,698.31
A	2,000,000.00	
	4,167,018.57	3,078,519.04
	107,749,227.52	102,252,886.68

Notes to the Financial Statements

F [illegible] J 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(VII) Inventories

	Balance as at the end of the period			B [illegible]	
Category	Book balance	Provision for decline in the value of inventories/ impairment provision for contract performance costs	Book value	B [illegible]	B [illegible]
[illegible]	1,230,185.02		1,230,185.02	1,616,778.62	1,616,778.62
G [illegible]	541,753.33		541,753.33	4,571,610.82	4,571,610.82
C [illegible]	50,117,702.41		50,117,702.41	54,411,790.81	54,411,790.81
[illegible]	51,889,640.76		51,889,640.76	60,600,180.25	60,600,180.25

(VIII) Other current assets

Items	Balance as at the end of the period	B [illegible]
[illegible]	2,006,813.22	205,753.33
[illegible]		4,368.35
[illegible]	1,046,974.56	647,898.71
[illegible]	3,053,787.78	858,020.39

(IX) Long-term receivables

	Balance as at the end of the period			B [illegible]		
Item	Book balance	Provision for bad debts	Book value	B [illegible]	B [illegible]	D [illegible]
[illegible]	14,000,000.00		14,000,000.00	14,000,000.00	14,000,000.00	
[illegible]	14,000,000.00		14,000,000.00	14,000,000.00	14,000,000.00	

X. Long-term equity investments

Investees	Balance of the impairment provision as at the end of the previous year	Increase/decrease in the current period								Balance as at the end of the period	Balance of the impairment provision as at the end of the period
		Increase in investment	Decrease in investment	Investment profit/loss recognized under equity method	Other comprehensive income adjustment	Other equity changes	Cash dividends or profits declared and paid	Impairment provision	Others		
A											
	16,018,884.98			687,659.39						16,706,544.37	
	56,841,432.86			-166,415.53						56,675,017.33	
	21,561,607.67			-393,224.24						21,168,383.43	
	22,287,534.75			712,327.54						22,999,862.29	
	18,649,398.65			-31,479.31						18,617,919.34	
	3,713,128.14	2,000,000.00		-330,039.89						5,383,088.25	
	139,071,987.05	2,000,000.00		478,827.96						141,550,815.01	

Notes to the Financial Statements

F [illegible] J[illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C[illegible])

(XI) Other non-current financial assets

I	Balance as at the end of the period	B [illegible]
F[illegible]	64,751,652.55	65,099,055.34
[illegible]	64,751,652.55	65,099,055.34
	64,751,652.55	65,099,055.34

(XII) Fixed assets

1. F[illegible]

Items	Balance as at the end of the period	B [illegible]
F[illegible] D[illegible]	782,127,103.00	794,856,342.94
	782,127,103.00	794,856,342.94

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(XII) Fixed assets *(Continued)*

2. D

I	Buildings and structure	Medical equipment	Motor vehicles	Electronic and other equipment	Fixed assets leased under sale-and-leaseback finance leases	Total
1.						
(1) B	870,189,179.09	80,978,235.73	13,585,774.73	62,896,115.93	101,426,794.17	1,129,076,099.65
(2)	1,349,135.60	8,331,368.92	767,123.03	3,310,931.83		13,758,559.38
	1,349,135.60	8,331,368.92	767,123.03	3,310,931.83		13,758,559.38
(3) D		4,377,292.00		965,585.92		5,342,877.92
D		4,377,292.00		965,585.92		5,342,877.92
(4) B	**871,538,314.69**	**84,932,312.65**	**14,352,897.76**	**65,241,461.84**	**101,426,794.17**	**1,137,491,781.11**
2. A						
(1) B	141,204,440.95	58,760,403.20	8,132,499.35	44,567,939.35	81,554,473.86	334,219,756.71
(2)	12,815,495.67	5,944,250.78	574,787.27	4,259,232.29	2,347,658.56	25,941,424.57
	12,815,495.67	5,944,250.78	574,787.27	4,259,232.29	2,347,658.56	25,941,424.57
(3) D		3,982,635.56		813,867.61		4,796,503.17
D		3,982,635.56		813,867.61		4,796,503.17
(4) B	**154,019,936.62**	**60,722,018.42**	**8,707,286.62**	**48,013,304.03**	**83,902,132.42**	**355,364,678.11**
3. I						
(1) B						
(2)						
(3) D						
(4) B						
4. C						
(1) C	717,518,378.07	24,210,294.23	5,645,611.14			
					end of the period	714,440.95

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

[illegible]. [illegible] (C [illegible])

(XIII) Construction in progress

1. C [illegible]

Items	Balance as at the end of the period			B [illegible]		
	Book balance	Impairment provision	Carrying amount	B [illegible]	I [illegible]	C [illegible]
C [illegible] C [illegible]	234,034,296.61		234,034,296.61	186,980,240.67		186,980,240.67
	234,034,296.61		234,034,296.61	186,980,240.67		186,980,240.67

2. D [illegible]

Items	Balance as at the end of the period			B [illegible]		
	Book balance	Impairment provision	Carrying amount	B [illegible]	I [illegible]	C [illegible]
H [illegible]	137,317,869.97		137,317,869.97	101,029,929.74		101,029,929.74
C [illegible] H [illegible]	89,526,711.76		89,526,711.76	85,174,600.41		85,174,600.41
H C [illegible]	3,766,450.99		3,766,450.99			
[illegible]	3,423,263.89		3,423,263.89	775,710.52		775,710.52
	234,034,296.61		234,034,296.61	186,980,240.67		186,980,240.67

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(XIV) Right-of-use assets

Items	Buildings and structure	Total
1.		
(1) B	301,405,111.73	301,405,111.73
(2)	70,408.22	70,408.22
	70,408.22	70,408.22
(3) D	1,131,585.84	1,131,585.84
	1,131,585.84	1,131,585.84
(4) B	**300,343,934.11**	**300,343,934.11**
2. A		
(1) B	112,350,605.05	112,350,605.05
(2)	18,029,069.41	18,029,069.41
	18,029,069.41	18,029,069.41
(3) D	500,865.89	500,865.89
	500,865.89	500,865.89
(4) B	**129,878,808.57**	**129,878,808.57**
3. I		
(1) B		
(2)		
(3) D		
(4) B		
4. C		
(1) C	**170,465,125.54**	**170,465,125.54**
(2) C	189,054,506.68	189,054,506.68

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

[illegible] (C [illegible])

(XV) Intangible assets

I	Land use rights	Trademark rights	Software	Medical practice qualifications	Contractual rights to provide management services	Total
1. [illegible]						
(1)B [illegible]	154,962,176.05	3,061,637.13	16,215,218.87	216,837,000.00	32,400,000.00	423,476,032.05
(2)[illegible]	13,635.58		1,978,663.72			1,992,299.30
[illegible]	13,635.58		1,978,663.72			1,992,299.30
(3)D [illegible]						
(4)B [illegible]	**154,975,811.63**	**3,061,637.13**	**18,193,882.59**	**216,837,000.00**	**32,400,000.00**	**425,468,331.35**
2. A [illegible]						
(1)B [illegible]	20,300,242.06	1,077,654.89	8,107,861.28	62,972,140.09	10,696,428.57	103,154,326.89
(2)[illegible]	1,560,910.96	163,620.15	1,319,911.39	10,529,799.87	864,285.71	14,438,528.08
[illegible]	1,560,910.96	163,620.15	1,319,911.39	10,529,799.87	864,285.71	14,438,528.08
(3)D [illegible]						
(4)B [illegible]	**21,861,153.02**	**1,241,275.04**	**9,427,772.67**	**73,501,939.96**	**11,560,714.28**	**117,592,854.97**
3. I [illegible]						
(1)B [illegible]						
(2)[illegible]						
(3)D [illegible]						
(4)B [illegible]						
4. C [illegible]						
(1)C [illegible]	**133,114,658.61**	**1,820,362.09**	**8,766,109.92**	**143,335,060.04**	**20,839,285.72**	**307,875,476.38**
(2)C [illegible]	**134,661,933.99**	**1,983,982.24**	**8,107,357.59**	**153,864,859.91**	**21,703,571.43**	**320,321,705.16**

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

[illegible] [illegible] (C [illegible])

(XVI) Goodwill

1. C[illegible]

Name of the investees or events generating goodwill	B [illegible]	Increase in the current period		Decrease in the current period		Balance as at the end of the period
		Arising from business combination	Increase of provision for goodwill impairment	Disposal	Disposal of goodwill impairment	
[illegible] H C., [illegible] 9,271,800.00	9,271,800.00					9,271,800.00
H [illegible] H C., [illegible] 690,331.47	690,331.47					690,331.47
G [illegible] H C., [illegible] 1,549,022.38	1,549,022.38					1,549,022.38
D [illegible] H C., [illegible] 7,784,850.00	7,784,850.00					7,784,850.00
B [illegible] H C., [illegible] 22,987,331.04	22,987,331.04					22,987,331.04
[illegible] H [illegible] C., [illegible] 151,048.40	151,048.40					151,048.40
H [illegible] H C., [illegible] 5,068,959.78	5,068,959.78					5,068,959.78
C[illegible] H C., [illegible] 6,843,288.91	6,843,288.91					6,843,288.91
[illegible] C[illegible] H C., [illegible] 19,416,285.97	19,416,285.97					19,416,285.97
C[illegible] H C., [illegible] 51,770,194.67	51,770,194.67					51,770,194.67
H[illegible] C., [illegible] 1,272,643.00	1,272,643.00					1,272,643.00
J[illegible] H C., [illegible] 5,060,323.85	5,060,323.85					5,060,323.85
C[illegible] H C., [illegible] 283,528.10	283,528.10					283,528.10
D[illegible] H C., [illegible] 2,502,854.13	2,502,854.13					2,502,854.13
C[illegible] H C., [illegible] 9,564,442.65	9,564,442.65					9,564,442.65
[illegible] A [illegible] C., [illegible] 228,538.31	228,538.31					228,538.31
[illegible]	144,445,442.66					144,445,442.66
I [illegible] B [illegible] H C., [illegible] 22,987,331.04	22,987,331.04					22,987,331.04
G [illegible] H C., [illegible] 1,549,022.38	1,549,022.38					1,549,022.38
[illegible]	24,536,353.42					24,536,353.42
C[illegible]	119,909,089.24					119,909,089.24

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(XVI) Goodwill *(Continued)*

2. [illegible]

[illegible] *B'0,000*

Name of goodwill asset groups or portfolio of asset groups	Composition and basis of asset groups or portfolio of asset groups	Carrying amount as at the end of the period	Consistent with the prior years or not
[illegible] H [illegible] C., [illegible]	A [illegible]	1,342.46	
H [illegible] H [illegible] C., [illegible]	A [illegible]	1,645.65	
G [illegible] H [illegible] C., [illegible]	A [illegible]	1,074.50	
[illegible] H [illegible] C., [illegible]	A [illegible]	771.11	
B [illegible] H [illegible] C., [illegible]	A [illegible]	4,178.64	
[illegible] H [illegible] C., [illegible]	A [illegible]	14.48	
H [illegible] H [illegible] C., [illegible]	A [illegible]	552.41	
C [illegible] H [illegible] C., [illegible]	A [illegible]	1,278.50	
[illegible] C [illegible] H [illegible] C., [illegible]	A [illegible]	3,726.83	
[illegible] C [illegible] H [illegible] C., [illegible]	A [illegible]	12,548.35	
H [illegible] C., [illegible]	A [illegible]	181.32	
J [illegible] H [illegible] C., [illegible]	A [illegible]	7,011.47	
[illegible] H [illegible] C., [illegible]	A [illegible]	2,485.39	
D [illegible] H [illegible] C., [illegible]	A [illegible]	2,179.53	
C [illegible] J [illegible] H [illegible] C., [illegible]	A [illegible]	2,792.84	
[illegible] A [illegible] C., [illegible]	A [illegible]	4.09	
[illegible]		41,787.57	

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(XVII) Long-term prepaid expenses

Items	B [illegible]	Increase in the current period	Amortisation in the current period	[illegible]	Balance as at the end of the period
[illegible]	175,706,029.27	1,863,337.07	21,012,423.47		156,556,942.87
	178,292.93	38,000.00	41,641.68		174,651.25
	26,303.94		7,316.61		18,987.33
	175,910,626.14	1,901,337.07	21,061,381.76		156,750,581.45

(XVIII) Deferred tax assets and deferred tax liabilities

1. D [illegible]

Items	Balance as at the end of the period		B [illegible]	
	Deductible temporary differences	Deferred tax assets	D [illegible]	D [illegible]
[illegible]	37,735,416.76	7,995,190.93	25,318,013.56	5,221,670.24
	36,307,991.72	9,076,997.93	3,073,067.80	3,073,067.80
D [illegible]	94,761,661.96	18,358,697.14	126,627,704.89	26,623,506.01
	178,203,515.38	44,007,128.21	181,046,756.88	45,261,689.23
[illegible]	55,456,176.01	8,308,050.85	54,688,502.33	8,203,275.35
	402,464,761.83	87,746,065.06	390,754,045.46	88,383,208.63

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

Notes to the Financial Statements

F J 30, 2024
(A B)

15.

(XX) Assets with restricted ownership or right-of-use

Items	As at the end of the period				A		C
	Book balance	Carrying amount	Types for restriction	Case for restriction	B	C	B
C	150,009.00	150,009.00	Guarantee	Bank acceptance deposit	772,510.54	772,510.54	E
	5,000,000.00	5,000,000.00	Guarantee	Performance bond	12,000,000.00	12,000,000.00	E
	1,363,135.53	1,363,135.53	Freezing	Foreign Exchange Control Account	1,361,750.73	1,361,750.73	F E C A E
					2,120.75	2,120.75	E
					2,000.00	2,000.00	E
Z	208,244,700.00	208,244,700.00	Pledge	Pledged loans	208,244,700.00	208,244,700.00	
F	104,902,010.82	104,902,010.82	Mortgage	Sale and leaseback	101,426,794.17	19,872,320.31	
	215,173,758.25	215,173,758.25	Mortgage	Secured borrowings	161,856,152.45	156,403,844.80	
	26,041,873.00	26,041,873.00	Mortgage	Secured borrowings	59,523,538.00	52,511,079.33	
	240,799,717.53	240,799,717.53			281,904,499.27	274,892,040.60	

(XXI) Short-term borrowings

Items	Balance as at the end of the period	B Z
	111,000,000.00	125,000,000.00
G		2,001,700.00
	111,000,000.00	127,001,700.00

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(XXII) Financial liabilities held for trading

Items	Balance as at the end of the period	B [illegible]
F [illegible]	12,400,000.00	12,400,000.00

(XXIII) Accounts payable

[illegible] :

Items	Balance as at the end of the period	B [illegible]

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

[illegible]

(XXVI)

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

5. [illegible] (C [illegible])

(XXVI) Employee benefits payable *(Continued)*

3. [illegible]

Items	B [illegible]	Increase in the current period	Decrease in the current period	Balance as at the end of the period
B [illegible]	4,118,499.45	17,853,475.62	19,109,187.58	2,862,787.49
[illegible]	141,199.04	593,688.95	648,098.81	86,789.18
[illegible]	4,259,698.49	18,447,164.57	19,757,286.39	2,949,576.67

[illegible] C [illegible] G [illegible]

(XXVII) Taxes payable

Items	Balance as at the end of the period	B [illegible]
[illegible] (5A)	2,694,016.67	3,056,261.74
E [illegible]	22,926,288.67	30,600,774.99
[illegible]	1,720,787.95	1,148,089.23
C [illegible]	104,506.51	134,739.29
[illegible]	3,012,925.99	2,960,159.04
[illegible]	74,789.97	96,590.18
[illegible]	305,640.50	523,438.18
[illegible]	13,843.13	31,053.22
E [illegible]	2,094.00	1,869.00
F [illegible]	552.42	771.60
[illegible]	30,855,445.81	38,553,746.47

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(XXVIII) Other payables

Items	Balance as at the end of the period	B Z
		35,313.43
DZ	2,370,000.00	624,000.00
	66,117,137.05	149,611,261.72
	68,487,137.05	150,270,575.15

1.

Items	Balance as at the end of the period	B Z
	35,313.43	
	35,313.43	

2. Z

Items	Balance as at the end of the period	B Z
DZ	2,370,000.00	624,000.00
	2,370,000.00	624,000.00

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(XXVIII) Other payables *(Continued)*

3.

Items	Balance as at the end of the period	B Z
/	17,785,659.46	62,637,634.31
/	1,313,457.77	1,313,457.77
	1,740,116.45	6,766,360.73
D G	1,237,034.24	1,663,762.95
C	29,986,754.10	38,542,529.94
/	3,677,029.66	9,845,641.28
A	8,254,225.35	28,481,495.22
	2,122,860.02	360,379.52
	66,117,137.05	149,611,261.72

(XXIX) Non-current liabilities due within one year

Items	Balance as at the end of the period	B Z
	44,136,233.34	180,020,000.00
	41,370,743.00	41,747,868.00
	22,779,404.91	28,643,888.99
	108,286,381.25	250,411,756.99

Notes to the Financial Statements

F J 30, 2024
(A B)

5. (C)

(XXX) Other current liabilities

Items	Balance as at the end of the period	B Z
5A	5,575.47	
E	563,849.74	
	569,425.21	

(XXXI) Long-term borrowings

Items	Balance as at the end of the period	B Z
	89,166,233.34	212,842,127.25
G	306,620,000.00	252,010,000.00
	416,574,669.65	272,887,087.44
:	44,136,233.34	180,020,000.00
	768,224,669.65	557,719,214.69

(XXXII) Lease liabilities

Items	Balance as at the end of the period	B Z
	158,912,952.10	163,239,532.76
	158,912,952.10	163,239,532.76

Notes to the Financial Statements

F J 30, 2024

(A B)

15. (C)

(XXXIII) Long-term accounts payable

Items	Balance as at the end of the period	B Z
	64,227,913.88	61,351,340.53
	64,227,913.88	61,351,340.53

Items	Balance as at the end of the period	B Z
F	105,598,656.88	103,099,208.53
	15,254,200.16	15,109,210.13
	41,370,743.00	41,747,868.00
	64,227,913.88	61,351,340.53

(XXXIV) Deferred income

Items	B Z	Increase in the current period	Decrease in the current period	Balance as at the end of the period	
G Z	8,734,099.00		151,896.00	8,582,203.00	A
	8,734,099.00		151,896.00	8,582,203.00	

(XXXV) Share capital

Items	B Z	Increase (+) decrease (-) in the current period					Balance as at the end of the period
		Issuance of new shares	Bonus issue	conversion from reserves	others	Subtotal	
	74,600,300.00						74,600,300.00

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(XXXVI) Capital surplus

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
C	781,037,804.26		12,709,794.63	768,328,009.63
	44,857,374.20	767,673.68		45,625,047.88
	26,800,423.23			26,800,423.23
	852,695,601.69	767,673.68	12,709,794.63	840,753,480.74

(XXXVII) Treasury stock

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
C				
	12,587,011.74		9,440,179.03	3,146,832.71
	12,587,011.74		9,440,179.03	3,146,832.71

(XXXVIII) Surplus reserve

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
	38,399,577.13			38,399,577.13
	38,399,577.13			38,399,577.13

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(XXXIX) Retained earnings

Items	Amount for the current period	A [illegible]
[illegible]	311,956,229.16	233,506,534.43
A [illegible] (+, -)	311,956,229.16	233,506,534.43
A : [illegible]	50,723,744.20	85,947,806.64
: A [illegible]		
A [illegible]		
A [illegible]		
D [illegible]	22,380,090.00	7,498,111.91
D [illegible]		
[illegible]	340,299,883.36	311,956,229.16

(XL) Revenue and cost of sales

1. A [illegible]

	Amount for the current period		A [illegible]	
Items	Revenue	Cost	[illegible]	C [illegible]
[illegible]	765,636,198.08	555,217,793.42	728,692,633.43	547,491,901.17
[illegible]	63,321,355.63	47,582,667.69	49,232,530.41	28,898,694.59
[illegible]	828,957,553.71	602,800,461.11	777,925,163.84	576,390,595.76

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(XL) Revenue and cost of sales *(Continued)*

1. A (C)
B :

Items	Amount for the current period	A
	765,636,198.08	728,692,633.43
	765,636,198.08	728,692,633.43
	63,321,355.63	49,232,530.41
	41,715,643.36	28,881,807.57
	7,958,001.19	1,485,148.50
	297,619.53	2,857,971.77
	13,350,091.55	16,007,602.57
	828,957,553.71	777,925,163.84

2. D

Items	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
	A	B	D			

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(XLI) Taxes and charges

Items	Amount for the current period	A [illegible]
[illegible]	4,886,926.23	1,704,919.27
C [illegible]	460,954.07	398,619.06
E [illegible]	331,720.92	284,861.86
[illegible]	445,099.29	244,228.99
[illegible]	130,348.60	139,457.81
[illegible]	13,249.84	11,774.66
[illegible]	6,268,298.95	2,783,861.65

(XLII) Selling and distribution expenses

Items	Amount for the current period	A [illegible]
E [illegible]	5,264,561.40	4,571,354.43
D [illegible]	99,249.43	96,371.80
A [illegible]	21,787.27	22,513.69
A [illegible]	155,095.54	155,131.68
E [illegible]	435,531.57	316,393.31
[illegible]	316,961.17	180,167.93
[illegible]	179,730.55	167,234.65
[illegible]		10,478.18
[illegible]	219,294.83	235,841.00
[illegible]	2,388,776.86	2,020,072.51
[illegible]	139,038.00	25,268.40
[illegible]	29,239.82	27,782.42
[illegible]	9,249,266.44	7,828,610.00

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(XLIII) General and administrative expenses

Items	Amount for the current period	A
E	63,615,210.18	55,921,762.58
D	7,553,031.91	6,990,089.75
A	1,874,457.13	1,800,111.04
A	4,527,100.72	4,684,159.80	
	963,471.75	1,039,347.77
H	1,323,759.68	1,386,037.88
E	767,673.68	
	2,276,602.65	1,700,201.12
	2,198,731.91	2,070,528.66
	351,396.86	717,753.37
	2,919,344.90	1,676,255.06
C	1,024,421.20	1,263,793.76
	1,308,692.84	1,582,961.78
C	1,815,859.33	14,377,209.14
A	2,226,500.13	
	5,421,178.66	3,248,248.19
E	2,803,324.36	2,599,553.04
	3,300,625.81	866,013.82
	106,271,383.70	101,924,026.76

(XLIV) Research and development expenses

Items	Amount for the current period	A
E	17,015,841.55	13,998,896.69
D	313,121.72	191,563.81
	23,806.46	92,076.48	
	1,279.22	1,369.72
	7,292.41	388,988.66
	7,536.00	
	219,198.79	285,100.27
	17,588,076.15	14,957,995.63

Notes to the Financial Statements

F J 30, 2024
(A B)

5. (C)

(XLV) Financial expenses

Items	Amount for the current period	A
	23,323,466.98	19,182,137.46
:	5,245,075.86	5,058,106.16
:	2,686,209.46	2,704,831.09
F	99,244.67	-13,070.04
	3,728,948.96	3,695,397.63
	24,465,451.15	20,159,633.96

(XLVI) Other income

Items	Amount for the current period	A
G	5,386,176.18	5,600,421.10
A 5A	13,945.83	200,405.44
F	188,141.27	21,668.61
	5,588,263.28	5,822,495.15

(XLVII) Investment income

Items	Amount for the current period	A
	478,827.96	-157,522.45
	1,201,371.61	-38,203.48
	1,680,199.57	-195,725.93

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(XLVIII) Gain from change in fair value

Source of gains from changes in fair value	Amount for the current period	A
F	248,879.60	
	-347,402.79	
	-98,523.19	

(XLIX) Credit impairment losses

Items	Amount for the current period	A
	462,548.63	-3,047,374.71
	-6,046,812.64	37,447.94
	-5,584,264.01	-3,009,926.77

(L) Gain from disposal of assets

Items	Amount for the current period	A	A
G ( )	-75,116.21		-75,116.21
: G ( )	-75,116.21		-75,116.21
	130.80		130.80
	-74,985.41		-74,985.41

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

[illegible] (C [illegible])

(LIII) Income tax expenses

1. [illegible]

Items	Amount for the current period	A [illegible]
C [illegible]	19,082,552.41	23,358,206.57
D [illegible]	-2,566,409.06	-11,880,326.50
	16,516,143.35	11,477,880.07

2. [illegible]

Items	Amount for the current period
	61,512,576.64
[illegible]	12,647,013.90
I [illegible]	474,180.04
A [illegible]	-769,492.74
I [illegible]	
I [illegible]	817,638.14
I [illegible]	
[illegible]	-4,610,218.14
I [illegible]	
[illegible]	9,615,739.59
I [illegible]	-3,065,849.16
[illegible]	1,407,131.72
[illegible]	16,516,143.35

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

15. [illegible] (C [illegible])

(LIV) Earnings per share

1. B [illegible]

B [illegible] C [illegible] :

Items	Amount for the current period	A [illegible]
C [illegible]	50,723,744.20	43,750,057.46
C [illegible]	74,600,300.00	74,600,300.00
B [illegible]	0.68	0.59
[illegible] : B [illegible]	0.68	0.59
B [illegible]		

2. D [illegible]

D [illegible] C [illegible]):

Items	Amount for the current period	A [illegible]
C [illegible])	50,723,744.20	43,750,057.46
C [illegible])	74,600,300.00	74,600,300.00
D [illegible]	0.68	0.59
[illegible] : D [illegible]	0.68	0.59
D [illegible]		

Notes to the Financial Statements

F [illegible] J 30, 2024

(A B)

15. [illegible] (C)

(LV) Supplementary information to the cash flow statement

1. [illegible]

Supplementary information	Amount for the current period	A [illegible]
43,750,057.46		
1. [illegible]	44,996,433.29	43,750,057.46
A 43,750,057.46		

Notes to the Financial Statements

F J 30, 2024
(A B)

15. (C)

(LV) Supplementary information to the cash flow statement *(Continued)*

1. (C)

Supplementary information	Amount for the current period	A
2.		
C C		
3.		
C	366,789,288.94	262,868,904.62
: C	404,723,339.37	258,595,990.97
A : C : C		
	-37,934,050.43	4,272,913.65

2. *C*

Items	Balance as at the end of the period	B
I. C	366,789,288.94	262,868,904.62
: C	315,188.51	209,188.36
C	365,833,425.73	262,235,513.11
	640,674.70	424,203.15
II. C : B		
III. C	366,789,288.94	262,868,904.62
: C G		

For the six months ended June 30, 2024

(All amounts are expressed in RMB unless otherwise stated)

5. Changes in the scope of consolidation

(I) Disposal of subsidiaries

1.

Name of subsidiary	Disposal price at the date of loss of control	Percentage of disposals at the date of loss of control (%)	Disposal at the date of loss of control	Date of loss of control	Basis for determining the date of loss of control	Difference between the consideration for disposal and the share of net assets of the subsidiary at the level of the relevant consolidated financial statements in which the disposed investments presented	Percentage of remaining equity on the date of loss of control	Carrying amount of remaining equity at the level of the relevant consolidated financial statements in which on the date of loss of control	Fair value of remaining equity at the level of the relevant consolidated financial statements in which on the date of loss of control	Gain or loss on fair value remeasurement of remaining equity interests	Determination method and major assumptions of the fair value of remaining equity at the level of the relevant consolidated financial statements in which on the date of loss of control	Amount transferred into investment gain or loss/ retained earnings from other comprehensive income relating to the equity investment in the former subsidiary
H C ., (温州育己健康科技有限公司)	432,733.42	55.00		2024.1.1		-155,627.85						

(II) Changes in the scope of consolidation due to other reasons

1. 1, 2024, C , C H C .,

2. A 24, 2024, C - G H C .,

3. 24, 2024, C , G F H C ., (G) C .,

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

51. [illegible]

(I) Interests in subsidiaries

1. [illegible]

Name of Subsidiary	Type of legal entity	Registered capital (RMB'0,000)	Major business location	Place of registration	Nature of business	Shareholding (%) Direct	Shareholding (%) Indirect	Method of acquisition
[illegible]	C	20,000.00	[illegible]	[illegible]	[illegible]	100.00		[illegible]
[illegible]	C	600.00	[illegible]	[illegible]	[illegible]		100.00	[illegible]
[illegible]	C	6,000.00	[illegible]	[illegible]	[illegible]		100.00	[illegible]
[illegible]	C	3,000.00	[illegible]	[illegible]	[illegible]		60.00	[illegible]
[illegible]	C	1,000.00	[illegible]	[illegible]	[illegible]		51.00	[illegible]
[illegible]	C	3,000.00			[illegible]		100.00	[illegible]
[illegible]	C	1,000.00	[illegible]	[illegible]	[illegible]		51.00	C [illegible]
[illegible]	C	100.00	[illegible]	[illegible]	[illegible]		100.00	[illegible]
[illegible]	C	500.00	[illegible]	[illegible]	[illegible]		100.00	[illegible]
[illegible]	C	1,000.00	[illegible]	[illegible]	[illegible]		100.00	[illegible]
[illegible]	C	1,000.00	[illegible]	[illegible]	[illegible]		100.00	[illegible]
[illegible]	C	1,000.00	[illegible]	[illegible]	[illegible]		85.65	C [illegible]
[illegible]	C	3,000.00	[illegible]	[illegible]	[illegible]		51.00	C [illegible]
[illegible]	C	1,000.00	[illegible]	[illegible]	[illegible]		90.00	C [illegible]
[illegible]	C	753.00	[illegible]	[illegible]	[illegible]		68.80	C [illegible]
[illegible]	C	4,653.67	[illegible]	[illegible]	[illegible]		67.77	[illegible]
[illegible]	C	50.00	[illegible]	[illegible]	[illegible]		100.00	C [illegible]
[illegible]	C	1,000.00	[illegible]	[illegible]	[illegible]		95.00	C [illegible]

Notes to the Financial Statements

F [illegible] J 30, 2024

(A [illegible] B [illegible])

Name of Subsidiary	Type of legal entity	Registered capital (RMB'0,000)	Major business location	Place of registration	Nature of business	Shareholding (%) Direct	Shareholding (%) Indirect	Method of acquisition
[illegible]								
	C	2,040.82	H	H	Z		98.00	
D C	C	50.00			D		100.00	
H ( )					H			
C	C	500.00					100.00	
D C	C	1,000.00					80.00	
H								C
C	C	2,200.00	C	C			64.55	
E &D								
C	C	500.00	H	H	Z		100.00	
Z C	C	100.00	H	H			100.00	
C H C	C	5,000.00			Z		100.00	
H	C	6,000.00			Z		55.00	
H H C								
(								

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

51. [illegible] (C [illegible])

(I) Interests in subsidiaries *(Continued)*

1. [illegible]

Name of Subsidiary	Type of legal entity	Registered capital (RMB'0,000)	Major business location	Place of registration	Nature of business	Shareholding (%) Direct	Shareholding (%) Indirect	Method of acquisition
[illegible]	C	3,057.47	[illegible]	[illegible]	[illegible]	100.00		C [illegible]
[illegible]	C	9,800.00	[illegible]	[illegible]	[illegible]	100.00		C [illegible]
[illegible]	C	2,398.26	[illegible]	[illegible]	[illegible]	55.00		C [illegible]
[illegible]	C	1,940.00	[illegible]	[illegible]	[illegible]	51.00		C [illegible]
[illegible]	C	3,000.00	[illegible]	[illegible]	[illegible]		100.00	[illegible]
[illegible]	C	100.00	[illegible]	[illegible]	[illegible]		100.00	C [illegible]
[illegible]	C	1,800.00	[illegible]	[illegible]	[illegible]	51.00		C [illegible]
[illegible]	C	50.00	[illegible]	[illegible]	[illegible]	100.00		[illegible]
[illegible]	C	6,001.00	[illegible]	[illegible]	[illegible]	66.60	33.30	[illegible]
[illegible]	C	2,083.33	[illegible]	[illegible]	[illegible]		49.33	C [illegible]
[illegible]	C	1,000.00	[illegible]	[illegible]	[illegible]		100.00	[illegible]
[illegible]	C	20,000.00	[illegible]	[illegible]	[illegible]	100.00		[illegible]

E [illegible]:

A [illegible] G [illegible] H [illegible] 100%.

Notes to the Financial Statements

F [illegible] J 30, 2024
(A [illegible] B [illegible])

51. [illegible] (C [illegible])

(I) Interests in subsidiaries *(Continued)*

2. [illegible]

Name of Subsidiary	Shareholding percentage of non-controlling shareholder	Current profits or losses attributable to non-controlling shareholders	Current dividends distributed to non-controlling shareholders	Closing balance of interest of non-controlling shareholders
[illegible] H [illegible] C ., .	40.00%	44,686.00		30,411,626.36
J [illegible] H [illegible] C ., .	45.00%	-1,622,191.24		16,064,103.54

3. [illegible]

	Balance as at the end of the period						B [illegible] Z					
Name of Subsidiary	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities	C [illegible]			C [illegible]		
[illegible] H C ., .	8,793,123.17	162,275,430.25	171,068,553.42	39,487.47	95,000,000.00	95,039,487.47	12,771,926.28	126,317,515.02	139,089,441.30	48,340.35	75,123,750.00	75,172,090.35
J [illegible] H C ., .	8,951,720.53	70,164,028.21	79,115,748.74	14,151,720.45	28,010,857.21	42,162,577.66	13,868,975.32	71,012,513.90	84,881,489.22	15,643,448.52	28,680,000.20	44,323,448.72

	Amount for the current period				A [illegible] Z			
Name of Subsidiary	Revenue	Net profit	Total comprehensive income	Cash flows from operating activities	Z		C Z	Z
[illegible] H C ., .		111,715.00	111,715.00	7,479,658.56		-1,000,974.74	-1,000,974.74	-3,869,458.16
J [illegible] H C ., .	9,111,507.81	-3,604,869.42	-3,604,869.42	-2,290,097.91	16,050,977.70	-2,852,161.57	-2,852,161.57	-8,603,908.46

Notes to the Financial Statements

F J 30, 2024
(A B)

51. (C)

(II) Transactions that cause changes in the share of owners' equity in subsidiaries that do not result in loss of control

1. E

F 2024, B
H C ., .,
B A
( )
B0.3 B1
B15,300,000.00.
B H C ., B46,536,700.00,
C 51% 67.77%.

A C
B3,375,411.44,
( )

(III) Interests in joint arrangements or associates

1.

Name of joint venture or associate	Major business location	Place of registration	Nature of business	Shareholding (%)		Accounting method for investment in joint ventures or associates	Whether strategic to the Company's activities or not
				Direct	Indirect		
H C ., .				45.00		E	
H C C ., .			H		30.00	E	

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

51. [illegible] (C [illegible])

(III) Interests in joint arrangements or associates *(Continued)*

2. [illegible]

	Closing balance/amount for the current period		[illegible]	
	Wenzhou Longwan Yining Hospital Co., Ltd.	Shaanxi Shanda Hospital Management Consulting Co., Ltd.	[illegible] H C., .	H C., .
C	5,919,113.19	44,911,330.78	46,656,767.88	71,300,257.36
	192,825,147.06	112,258,865.02	152,199,429.22	117,230,334.02
	198,744,260.25	157,170,195.80	198,856,197.10	188,530,591.38
C	37,799,777.29	80,049,646.18	37,541,901.86	97,460,588.12
	35,000,000.00	454,341.99	35,000,000.00	15,000,000.00
	72,799,777.29	80,503,988.17	72,541,901.86	112,460,588.12
		17,565,753.51		19,343,974.26
E	125,944,482.96	59,100,454.12	126,314,295.24	56,726,029.00
	56,675,017.33	22,999,862.29	56,841,432.86	22,821,000.98
A G C F				
		45,293,374.09		47,654,671.86
	-369,812.28	2,374,425.12	-257,993.98	1,052,984.93
	-369,812.28	2,374,425.12	-257,993.98	1,052,984.93
D				

Notes to the Financial Statements

F J 30, 2024
(A B)

III.

(I) Various risks associated with financial instruments

D C). C C C

Notes to the Financial Statements

F J 30, 2024
(A B)

II. (C)

(I) Various risks associated with financial instruments *(Continued)*

1. (C)

C A C C F C F C 2-9 C CZ A
B D F C

2.

I C C B 12 C A C

Notes to the Financial Statements

F J 30, 2024
(A B)

II. (C)

(I) Various risks associated with financial instruments *(Continued)*

2. (C)

C :

	Closing balance					
Items	Instant repayment	Within 1 year	1-2 years	2-5 years	Over 5 years	Total undiscounted contract amount	Book value
A		112,544,938.03				112,544,938.03	112,544,938.03
		68,487,137.05				68,487,137.05	68,487,137.05
		111,000,000.00				111,000,000.00	111,000,000.00
		108,286,381.25				108,286,381.25	108,286,381.25
			287,545,000.00	314,094,120.00	166,585,549.65	768,224,669.65	768,224,669.65
			18,133,866.38	54,983,512.27	95,622,594.14	168,739,972.79	158,912,952.10
			25,945,947.15	45,352,431.95		71,298,379.10	64,227,913.88
		400,318,456.33	331,624,813.53	414,430,064.22	262,208,143.79	1,408,581,477.87	1,210,651,916.88

	B					
I		1	1-2	2-5	5	B
		1,545,021.09				1,545,021.09	1,545,021.09
B		340,005,699.32	270,474,264.25	228,670,426.19	158,782,942.13	997,933,331.89	864,740,914.69
		28,643,888.99	44,408,365.80	71,261,748.80	69,158,488.54	213,472,492.13	191,883,421.75
		43,175,648.00	19,331,148.00	55,701,622.66		118,208,418.66	103,099,208.53
A		110,060,007.67				110,060,007.67	110,060,007.67
		150,270,575.15				150,270,575.15	150,270,575.15
		673,700,840.22	334,213,778.05	355,633,797.65	227,941,430.67	1,591,489,846.59	1,421,599,148.88

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

[illegible] II. [illegible] (C [illegible])

(I) Various risks associated with financial instruments *(Continued)*

3. [illegible]

(1) [illegible]

[illegible]

[illegible]

[illegible] J [illegible] 30, 2024, [illegible] C [illegible] B [illegible]

Notes to the Financial Statements

F J 30, 2024
(A B)

II. (C)

(I) Various risks associated with financial instruments *(Continued)*

3. (C)

(2) E

E

C

C

C B :

Items	Closing balance			B		
	US$	Other foreign currencies	Total	$		
C	285,090.74	45,278.51	330,369.25	81,905.11	52,061.43	133,966.54
	285,090.74	45,278.51	330,369.25	81,905.11	52,061.43	133,966.54

J 30, 2024, C B9,911.08 (D 31, 2023: B4,019.00) B 3%.

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

[illegible] II. [illegible] (C [illegible])

(I) Various risks associated with financial instruments *(Continued)*

3. [illegible] *(C [illegible])*

(3) [illegible]

[illegible] C [illegible]

[illegible] J [illegible] 30, 2024, [illegible] C [illegible] B2,170,524.92 (2023: B2,269,330.55), [illegible] 3%, [illegible] 3% [illegible]

[illegible] III. D [illegible]

[illegible]:

[illegible] 1 [illegible] ([illegible]) [illegible] C [illegible]

[illegible] 2 [illegible] [illegible] 1 [illegible]

[illegible] 3 [illegible]

[illegible]

Notes to the Financial Statements

F [illegible] J 30, 2024

(A [illegible] B [illegible])

III. D [illegible] (C [illegible])

(I) Closing fair value of assets and liabilities measured at fair value

Items	Closing fair value			
	Measured at fair value at Level 1	Measured at fair value at Level 2	Measured at fair value at Level 3	Total
I. Continuous measurement of fair value				
F [illegible]			7,599,178.13	7,599,178.13
1. F [illegible]			7,599,178.13	7,599,178.13
(1) [illegible]				
(2) [illegible]			7,599,178.13	7,599,178.13
2. F [illegible]			64,751,652.55	64,751,652.55
1. F [illegible]			64,751,652.55	64,751,652.55
(1) [illegible]				
(2) [illegible]			64,751,652.55	64,751,652.55
Total assets with continuous measurement of fair value			72,350,830.68	72,350,830.68
F [illegible]			12,400,000.00	12,400,000.00
1. F [illegible]			12,400,000.00	12,400,000.00
(1) E [illegible]				
(2) D [illegible]				
(3) [illegible]			12,400,000.00	12,400,000.00
2. F [illegible]				
Total liabilities with continuous measurement of fair value			12,400,000.00	12,400,000.00

Notes to the Financial Statements

F [illegible] J 30, 2024
(A B)

III. D [illegible] (C)

(II) Qualitative and quantitative information of valuation techniques and key parameters adopted for items measured at the fair value of level 3 on a going and non-going concern

1. [illegible]

2. [illegible] C H [illegible] C [illegible]

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

I . [illegible]

(I) General information of the parent company

[illegible] C [illegible] : G [illegible]

(II) Information of the Company's subsidiaries

D [illegible] C [illegible]

(III) Information of the Company's joint ventures and associates

F [illegible] C [illegible]

[illegible] C [illegible]

Name of joint venture or associate	Relationship with the Company
H [illegible] A [illegible] C [illegible]	A [illegible] C [illegible]
H [illegible] C [illegible]	A [illegible] C [illegible]
H [illegible] H [illegible] C [illegible]	A [illegible] C [illegible]
H [illegible] C [illegible] C [illegible]	A [illegible] C [illegible]
H [illegible] H [illegible] C [illegible]	A [illegible] C [illegible]
F [illegible] C [illegible]	A [illegible] C [illegible]

Notes to the Financial Statements

F J 30, 2024
(A B)

I . (C)

(IV) Information of other related parties

Name of other related parties	Other related parties' relationship with the Company
C C G J D B A LZ ( ) (寧波梅山保稅港區寬展投資管理合夥企業(有限合夥))	C C C C
F H C H	C C C
H C (四川省宏濟藥業有限責任公司)	C C C C
C H C	D C Z C
E Z C C C H H C	C C I C
A C C H C	C C

Notes to the Financial Statements

F J 30, 2024
(A B)

I .

(V) Information on related party transactions

1.

Related party	Amount for the period	A
F A C ., .	46,490.62	
C ., .	17,960.18	

Related party	Amount for the period	A
H C	1,485,148.52	1,485,148.50
H H C ., .	84,905.66	

Notes to the Financial Statements

F [illegible] J 30, 2024
(A [illegible] B [illegible])

I. [illegible] (C [illegible])

(V) Information on related party transactions *(Continued)*

2. [illegible]
C [illegible]:

Name of guaranteed party	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
[illegible] H [illegible] C., [illegible].	14,660,000.00	2019/9/10	2029/8/20	
[illegible] H [illegible] C., [illegible].	10,280,000.00	2020/1/1	2029/8/20	
[illegible] H [illegible] C., [illegible].	3,320,000.00	2020/12/22	2029/8/20	
[illegible] H [illegible] C., [illegible].	2,200,000.00	2020/9/27	2029/8/20	
[illegible] H [illegible] C., [illegible].	2,200,000.00	2020/9/27	2029/8/20	
[illegible] H [illegible] C., [illegible].	3,050,000.00	2021/3/1	2029/8/20	
[illegible] H [illegible] C., [illegible].	3,050,000.00	2021/3/1	2029/8/20	
[illegible] H [illegible] C., [illegible].	45,000,000.00	2023/7/3	2037/12/31	
[illegible] H [illegible] C., [illegible].	15,000,000.00	2023/7/31	2037/12/31	
[illegible] H [illegible] C., [illegible].	10,116,550.00	2023/10/25	2037/12/31	
[illegible] H [illegible] C., [illegible].	5,007,200.00	2023/11/24	2037/12/31	
[illegible] H [illegible] C., [illegible].	5,000,000.00	2020/3/25	2024/12/20	
[illegible] H [illegible] C., [illegible].	17,500,000.00	2020/5/22	2024/12/20	
[illegible] H [illegible] C., [illegible].	60,000,000.00	2023/10/9	2031/10/9	
[illegible] H [illegible] C., [illegible].	2,000,000.00	2023/3/31	2024/3/29	
[illegible] C [illegible] H [illegible] C., [illegible].	26,000,000.00	2023/4/3	2032/3/2	

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

I . [illegible] (C [illegible])

(V) Information on related party transactions *(Continued)*

2. [illegible] (C [illegible])

C [illegible] :

Name of guarantor	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
[illegible] H [illegible] C ., [illegible] .	200,000,000.00		2026/12/24	
[illegible] H [illegible] C ., [illegible] .	200,000,000.00		2026/12/24	
C [illegible] H [illegible] C ., [illegible] .	200,000,000.00		2026/12/24	
C [illegible] H [illegible] C ., [illegible] .	66,474,000.00		2026/12/10	
[illegible] H [illegible] C ., [illegible] .	200,000,000.00		2026/12/24	
G [illegible]	24,000,000.00	2020/6/30	2027/6/30	
G [illegible] H [illegible]	79,642,127.25	2021/11/29	2028/11/29	
G [illegible] H [illegible]	180,950,000.00	2020/10/26	2026/10/25	
G [illegible]	70,000,000.00	2023/11/8	2026/11/15	
G [illegible]	135,000,000.00	2023/12/14	2024/12/14	
G [illegible] H [illegible]	14,660,000.00	2019/9/10	2029/8/20	
G [illegible] H [illegible]	10,280,000.00	2020/1/1	2029/8/20	
G [illegible] H [illegible]	3,320,000.00	2020/12/22	2029/8/20	
G [illegible] H [illegible]	2,200,000.00	2020/9/27	2029/8/20	
G [illegible] H [illegible]	2,200,000.00	2020/9/27	2029/8/20	
G [illegible] H [illegible]	3,050,000.00	2021/3/1	2029/8/20	
G [illegible] H [illegible]	3,050,000.00	2021/3/1	2029/8/20	
G [illegible] H [illegible]	45,000,000.00	2023/7/3	2037/12/31	
G [illegible] H [illegible]	15,000,000.00	2023/7/31	2037/12/31	
G [illegible] H [illegible]	10,116,550.00	2023/10/25	2037/12/31	
G [illegible] H [illegible]	5,007,200.00	2023/11/24	2037/12/31	
G [illegible] H [illegible]	5,000,000.00	2020/3/25	2024/12/20	
G [illegible] H [illegible]	17,500,000.00	2020/5/22	2024/12/20	
G [illegible] E Z [illegible] C [illegible] C ., [illegible] C ., [illegible] .	60,000,000.00	2023/10/9	2031/10/9	

Notes to the Financial Statements

F J 30, 2024
(A B)

I . (C)

(V) Information on related party transactions *(Continued)*

3.

Related parties	Placement amount	Commencement date	Expiry date	Description
Placements from banks and other financial institutions				
	900,000.00	2023/1/14	2024/1/14	
C H	4,800,000.00	2023/6/7	2024/6/7	
H C .,	1,095,000.00	2023/9/29		
H C .,	2,508,250.00	2022/6/13		
	2,000,000.00	2022/6/15	2023/6/14	
Placements with banks and other financial institutions				
H C .,	13,500,000.00	2023/1/10	2026/1/9	
H H C .,	33,273,577.42	2020/11/19	2023/5/18	
H C .,	10,204,311.69	2015/6/1		B
C	3,490,447.08	2015/9/1		

4.

Item	Amount for the current period	A
	3,600,689.93	3,215,037.52
	436,155.63	

Notes to the Financial Statements

F J 30, 2024
(A B)

I . (C)

(VI) Receivables from and payables to related parties and other unsettled items

1.

Items	Related parties	Balance as at the end of the period		B	
		Book balance	Provision for bad debts	B	
A					
	H C .,			65,000.00	3,250.00
	H A				
	C .,	1,522.85	15.23	1,522.85	15.23
	H	635,000.00	6,350.00	635,000.00	6,350.00
	H C .,	23,066,977.13	23,066,977.13	34,005,471.02	1,700,273.55
	C .,	13,903,890.41	695,194.52	14,290,027.40	714,501.37
	C .,	10,204,311.69	10,204,311.69	10,204,311.69	10,204,311.69
	C	3,490,447.08	3,490,447.08	3,490,447.08	3,490,447.08
	H A				
	C .,	16,836.66	841.83	16,836.66	841.83
	C G	100,000.00	1,000.00	100,000.00	1,000.00
		80,004.00	800.04	80,004.00	800.04
	C	75,187.50	3,759.38	105,187.50	5,259.38
	J D	431,587.50	21,579.38	479,707.50	23,985.38

Notes to the Financial Statements

F J 30, 2024
(A B)

I . (C)

(VI) Receivables from and payables to related parties and other unsettled items *(Continued)*

2.

Items	Related parties	Book balance as at the end of the period	B
A	H A C .,	78,950.00	167,677.40
		3,833,341.95	3,702,846.16
		994,803.26	962,492.04
	F H C .,	3,677,029.66	3,599,626.28
	H	1,095,000.00	1,095,000.00
	H H C .,	4,839,241.37	2,021,750.00
	B A		6,347,133.33
	G		16,997,627.91
	C .,	2,508,250.00	3,108,250.00
	G	92,081.16	94,276.16
		2,333,369.95	2,261,567.19
	B A	291,842.74	291,842.74
	H H C .,	93,142.79	93,142.79
	H H C .,	19,983.98	19,983.98

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

I . [illegible] (C [illegible])

(VII) Five Individuals with Highest Remunerations

F [illegible] J [illegible] 2024, [illegible] (J [illegible] 2023: 0), [illegible] C [illegible] :

Items	Amount for the current period	A [illegible]
[illegible]	1,174,589.67	2,096,606.59
[illegible]	17,942.58	
[illegible]	1,192,532.25	2,096,606.59

Remuneration band	Number of individuals for the current period	[illegible]
500,000-1,000,000.00	3	4
[illegible] 1,000,000.00	0	1
[illegible]	3	5

Notes to the Financial Statements

F J 30, 2024
(A B)

(I) Summary of share-based payment

C :

1. E

J 13, 2018, C 2018 H E 2018, B C B C G J 29, 2018 A 20, 2018, C ( ), J ( ), E ( ), J ( ) ( ), 2,460,000 B10.47 . A D 31, 2021,

C :

48 J 2022. A J 30, 2024,
(J 30, 2023:).

Notes to the Financial Statements

F J 30, 2024
(A B)

(C)

(I) Summary of share-based payment *(Continued)*

2. H A

2023 27, 2023. H
A C
H A
H A
C H C
C
C
H H A 5%
C H A
3,730,015
B /
H A

H A ( )
36 364,100
( )
36 616,000
( )
52 335,000 . A J 30, 2024,
7 75,000
H A
101 1,240,100 .
1.66% C

Notes to the Financial Statements

F J 30, 2024
(A B)

(C)

(I) Summary of share-based payment *(Continued)*

2. *(C)*

C

C

C

48

(II) Equity-settled share-based payment

B B10.87 B10.47

A

A J 30, 2024, B45,625,047.88.

B767,673.68.

Notes to the Financial Statements

F [illegible] J 30, 2024
(A [illegible] B [illegible])

I. C [illegible]

(I) Significant commitments

1. C [illegible]

	June 30, 2024 D [illegible]	31, 2023
H [illegible] &	55,890,951.92	122,040,000.00
	55,890,951.92	122,040,000.00

2. [illegible]
A J 30, 2024, C [illegible]

(II) Contingencies

C [illegible]

II. E [illegible]

(I) Profit distribution

B [illegible] 2024 [illegible] C [illegible], B1.50 ( ) 10 [illegible] C [illegible].

Notes to the Financial Statements

F J 30, 2024
(A B)

III. C

C :

C

C C

A :

	Balance as at the end of the period	B
D /	52.58%	53.79%

5. Segment Information

(I) Segment Information

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

5. [illegible]

(I) Accounts receivable

1. A [illegible]

Aging	Balance as at the end of the period	B [illegible]
[illegible] 1 [illegible]	51,071,471.71	48,552,078.47
1-2 [illegible]	11,406,851.48	257,315.13
2-3 [illegible]	257,315.13	709,878.26
[illegible] 3 [illegible]	4,616,400.13	3,906,521.87
[illegible]	67,352,038.45	53,425,793.73
[illegible]	11,362,291.77	5,359,236.04
[illegible]	55,989,746.68	48,066,557.69

Notes to the Financial Statements

F J 30, 2024
(A B)

5. (C)

(I) Accounts receivable *(Continued)*

2. A

	Balance as at the end of the period					B				
	Book balance		Provision for bad debts			B				
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Carrying amount	A	(%)	A	(%)	C
	4,873,715.26	7.24	4,873,715.26	100.00		4,873,715.26	9.12	4,873,715.26	100.00	
	4,873,715.26	7.24	4,873,715.26	100.00		4,873,715.26	9.12	4,873,715.26	100.00	
	57,018,962.00	92.76	6,488,576.51	11.38	50,530,385.49	48,552,078.47	90.88	485,520.78	1.00	48,066,557.69
A	5,459,361.19	8.11			5,459,361.19					
	57,018,962.00	84.66	6,488,576.51	11.38	50,530,385.49	48,552,078.47	90.88	485,520.78	1.00	48,066,557.69
	67,352,038.45	100.00	11,362,291.77		55,989,746.68	53,425,793.73	100.00	5,359,236.04		48,066,557.69

:

	Balance as at the end of the period				B	
Items	Book balance	Provision for bad debts	Proportion of provision (%)	Reason for the provision	B	
	4,873,715.26	4,873,715.26	100.00	Not expect to be recoverable	4,873,715.26	4,873,715.26
	4,873,715.26	4,873,715.26			4,873,715.26	4,873,715.26

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

5. [illegible]

(I) Accounts receivable *(Continued)*

2. [illegible]

[illegible]:

Items	Balance as at the end of the period		
	Accounts receivable	Provision for bad debt	Proportion of provision (%)
[illegible]	57,018,962.00	6,488,576.51	11.38
[illegible]	57,018,962.00	6,488,576.51	

3. [illegible]

Category	B [illegible]	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
[illegible]	4,873,715.26					4,873,715.26
[illegible]	485,520.78	6,003,055.73				6,488,576.51
[illegible]	5,359,236.04	6,003,055.73				11,362,291.77

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

[illegible]

(II) Other receivables

Items	Balance as at the end of the period	B [illegible]
[illegible]	787,500.00	
D[illegible]	14,400,000.00	14,400,000.00
[illegible]	607,735,083.60	586,048,325.58
[illegible]	622,922,583.60	600,448,325.58

1. [illegible]

Items	Balance as at the end of the period	B [illegible]
[illegible]	787,500.00	
[illegible]	787,500.00	

2. D[illegible]

Item (or investee)	Balance as at the end of the period	B [illegible]
C[illegible] H[illegible] C[illegible]	4,400,000.00	4,400,000.00
[illegible] H[illegible] C[illegible]	10,000,000.00	10,000,000.00
[illegible]	14,400,000.00	14,400,000.00

Notes to the Financial Statements

F J 30, 2024

(A B)

5. (C)

(II) Other receivables *(Continued)*

3.

(1) D

Aging	Balance as at the end of the period	B
1	571,062,190.36	552,853,728.97
1 2	5,089,808.65	34,594,797.65
2 3	33,287,580.41	496,167.22
3	1,158,794.57	908,479.96
	610,598,373.99	588,853,173.80
	2,863,290.39	2,804,848.22
	607,735,083.60	586,048,325.58

(2) D

	Balance as at the end of the period					B				
	Book balance		Provision for bad debts			B				
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	(%)	A	(%)	B
	610,598,373.99	100.00	2,863,290.39	0.47	607,735,083.60	588,853,173.80	100.00	2,804,848.22	0.48	586,048,325.58
A	80,464,046.88	13.18	2,863,290.39	3.56	77,600,756.49	75,462,768.59	12.82	2,804,848.22	3.72	72,657,920.37
A	530,134,327.11	86.82			530,134,327.11	513,390,405.21				513,390,405.21
	610,598,373.99	100.00	2,863,290.39	/	607,735,083.60	588,853,173.80	100.00	2,804,848.22	/	586,048,325.58

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

5. [illegible]

(II) Other receivables *(Continued)*

3. [illegible]

(2) [illegible]

[illegible]:

[illegible]:

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
A [illegible]	80,464,046.88	2,863,290.39	3.56
A [illegible]	530,134,327.11		
	610,598,373.99	2,863,290.39	

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

5. [illegible]

(II) Other receivables *(Continued)*

3. [illegible]

(3) [illegible]

Provision for bad debts	Stage I 12-month ECL	Stage II Lifetime ECL (not credit impaired)	Stage III Lifetime ECL (credit impaired)	Total
[illegible]	2,804,848.22			2,804,848.22
[illegible]	58,442.17			58,442.17
[illegible]	2,863,290.39			2,863,290.39

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024
(A [illegible] B [illegible])

5. [illegible]

(II) Other receivables *(Continued)*

3. [illegible]

(3) [illegible]

C[illegible]:

B	Stage I 12-month ECL	Stage II Lifetime ECL (not credit impaired)	Stage III Lifetime ECL (credit impaired)	Total
B	588,853,173.80			588,853,173.80
B — II				
— III				
— II				
— I				
A	21,745,200.19			21,745,200.19
D				
B	610,598,373.99			610,598,373.99

Notes to the Financial Statements

F J 30, 2024
(A B)

5. (C)

(II) Other receivables *(Continued)*

3. (C)

(4)

Category	B	Changes in the current period: Provided for	Recovered or reversed	Written-back or written-off	Other changes	Balance as at the end of the period
	2,804,848.22	58,442.17				2,863,290.39
	2,804,848.22	58,442.17				2,863,290.39

(5)

Nature of receivables	Book balance as at the end of the period	B
A	530,134,327.11	513,390,405.21
	25,957,550.96	20,480,175.04
D	5,716,830.00	5,920,030.00
	181,832.86	767,065.13
A	48,607,833.06	48,295,498.42
	610,598,373.99	588,853,173.80

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

5. [illegible]

(III) Long-term equity investments

Items	Balance as at the end of the period			[illegible]	
	Book balance	Provision for impairment	Book value	[illegible]	[illegible]
[illegible]	698,830,684.03		698,830,684.03	691,561,513.66	691,561,513.66
[illegible]	94,549,945.13		94,549,945.13	94,421,925.51	94,421,925.51
Total	793,380,629.16		793,380,629.16	785,983,439.17	785,983,439.17

Notes to the Financial Statements

For the Six Months Ended June 30, 2024

(All amounts in RMB unless otherwise indicated)

5. Long-term equity investments (Continued)

(III) Long-term equity investments *(Continued)*

1.

Investees	Balance at the beginning of the period	Increase/decrease in the current period				Balance as at the end of the period	Balance of the impairment provision as at the end of the period
		Increase in investment	Decrease in investment	Provision for impairment for the current period	Others		
	15,500,000.00					15,500,000.00	
	500,000.00					500,000.00	
	204,666,253.87				43,684.64	204,709,938.51	
	52,697,737.50					52,697,737.50	
	2,133,258.38					2,133,258.38	
	27,687,093.11					27,687,093.11	
	32,856,644.25					32,856,644.25	
	4,799,071.39				4,272.04	4,803,343.43	
	53,500,000.00				15,660.04	53,515,660.04	
	40,800,000.00	7,200,000.00				48,000,000.00	
	10,000,000.00					10,000,000.00	
	154,744,700.00				5,553.65	154,750,253.65	
	29,051,800.00					29,051,800.00	
	40,954,955.16					40,954,955.16	
	14,510,000.00					14,510,000.00	
	500,000.00					500,000.00	
	6,660,000.00					6,660,000.00	
	691,561,513.66	7,200,000.00			69,170.37	698,830,684.03	

Notes to the Financial Statements

F [illegible] J [illegible] 30, 2024

(A [illegible] B [illegible])

5. [illegible] (C [illegible])

(III) Long-term equity investments *(Continued)*

2. [illegible]

B [illegible]

Investees	Increase/decrease in the current period									Balance as at the end of the period	Balance of the impairment provision as at the end of the period
	Increase in investment	Decrease in investment	Investment profit/loss recognized under equity method	Other comprehensive income adjustment	Other equity changes	Cash dividends or profits declared and paid	Impairment provision	Others			
A [illegible]											
H [illegible]											
[illegible]											
[illegible] C., [illegible]	16,018,884.98		687,659.39							16,706,544.37	
[illegible]											
H [illegible] C., [illegible]	56,841,492.86		-166,415.53							56,675,017.33	
[illegible] H [illegible]											
[illegible] C., [illegible]	21,561,607.67		-393,224.24							21,168,383.43	
[illegible]	94,421,925.51		128,019.62							94,549,945.13	

Notes to the Financial Statements

F J 30, 2024
(A B)

5. (C)

(IV) Revenue and cost of sales

1.

	Amount for the current period		A	C
Items	Revenue	Cost		
	185,247,902.83	130,785,130.41	174,575,542.75	130,786,397.79
	7,845,218.13		1,629,256.25	
	193,093,120.96	130,785,130.41	176,204,799.00	130,786,397.79

B :

Items	Amount for the current period	A
	185,247,902.83	174,575,542.75
	185,247,902.83	174,575,542.75
	7,845,218.13	1,629,256.25
	6,472,852.67	
	209,955.19	512,200.28
	1,162,410.27	1,117,055.97
	193,093,120.96	176,204,799.00

2. D

Item	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
	A	B	D			

Notes to the Financial Statements

F [illegible] J 30, 2024

(A [illegible] B [illegible])

[illegible]

(V) Investment income

Items	Amount for the current period	A [illegible]
[illegible]	14,061,318.98	
[illegible]	128,019.62	816,165.55
[illegible]		-1,591,713.27
[illegible]	14,189,338.60	-775,547.72

Definitions

A C	B
B H	B H C ., . (北京怡寧醫院有限公司), C A 17, 2015, C
B D B	C
C H	C H C ., . (蒼南康寧醫院有限公司), C J 15, 2012, C
C C	C C ., , (蒼南怡寧護理中心有限公司), C 9, 2021, C
C	C C
C H	C J H C ., . (Z C H C ., . (成都怡寧醫院有限公司)), J 29, 2010, C
C H	H C ., ., C, H B H E (C : 2120)
CG C	C G Z C A C1 H
C H	C H C ., . (長春康林心理醫院有限公司), C F 16, 2016, C
C H	C H H C ., . (淳安康寧黃鋒醫院有限公司), C A 16, 2020, C
D ( )	( ) C

Definitions

D ( )	( ) C , B1.00 , B
D H	D H C ., . (洞口樂寧醫院有限公司), C J 5, 2018, C
EG	C
G H	G H C ., . (溫州怡寧老年醫院有限公司), C 2, 2015, C
G	C
G H	G H C ., . (冠縣怡寧醫院有限公司), C 1, 2017, C
H ( )	C , B1.00 , B H E
H H	H H C ., . (菏澤怡寧精神病醫院有限公司), C A 6, 2017, C
H D H $	H
H	H A C
H	G E H
H E	E H

Definitions

Definitions

C	C D I A C3 H
C	B
( )	D G ( ), ( ) B E
C H	C H C ., . (平陽長庚怡寧醫院有限公司), C J 14, 2021, C
H	H C ., . (平陽康寧醫院有限公司), C 2, 2015, C
H	H H C ., . (浦江怡寧黃鋒醫院有限公司), C 3, 2018, C
C C	C H
DZ	B1.50 (Z) 10 J 30, 2024 EG I E I DIVIDE D
H	H C ., . (青田康寧醫院有限公司), C A 1, 2011, C
H	H C ., . (衢州怡寧醫院有限公司), C 20, 2015, C
	J 30, 2024

Definitions

C	B
B	C
F	F (C 571 H),
( )	( ) C B1.00 D ( ) H ( )
( )	( ) ( )
H	H (深圳怡寧醫院, H C ., . (深圳市怡寧醫院有限公司)), 22, 2014, C

Definitions

H ( ) C ., . (怡寧心理互聯網醫院(溫州)有限公司), C 10, 2020, C

H H C ., . (永嘉康寧醫院有限公司), C D 12, 2012, C

H H C ., . (樂清康寧醫院有限公司), C 3, 2013, C

H C H C ., . (樂清怡寧中西醫結合醫院有限公司), C A 4, 2006, C B C & H (樂清邦爾中西醫結合醫院有限公司)

%

溫州康寧醫院股份有限公